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as therapeutic targets. The findings 
presented in this thesis provide new 
information on the role of genetic 
risk factors in AD and may enable 
the development of novel treatment 
strategies for AD in the future.
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ABSTRACT 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that leads to memory 
impairment and eventually dementia. Neuropathologically, AD is characterized by senile plaques 
and neurofibrillary tangles (NFTs), composed of amyloid-β (Aβ) peptide and hyperphosphorylated 
protein tau, respectively. Other central features include synaptic and neuronal loss and inflammation. 
AD is genetically heterogeneous with over 20 genetic loci known to affect individual’s risk; however, 
the molecular mechanisms of these heritable risk factors are poorly understood. Currently, only 
symptomatic treatments for clinically defined AD are available, thus, studies leading to better 
understanding of the mechanisms underlying the pathogenesis of AD may provide opportunities for 
developing urgently needed therapeutic treatments. 
The aim of this thesis was to study the associations between the risk genes and pathological 
pathways in AD, and to assess and review the potential of DHCR24 and LRP1 as therapeutic targets. 
Minor alleles in the SLC24A4 and EPHA1 loci were found to nominally associate with increased levels 
of cerebrospinal fluid (CSF) Aβ, whereas the minor allele of FERMT2 locus nominally associated with 
increased total and phosphorylated tau levels in the CSF of AD patients. Polygenic risk score 
combining 22 AD loci associated with Aβ levels in the CSF of AD patients and in the temporal cortex 
of a neuropathological cohort. Interestingly, the activity of γ-secretase in the temporal cortex 
correlated with the polygenic risk score only when the strongest known genetic risk factor, APOE, 
was excluded. Expression of MS4A6A and FRMD4A significantly increased and decreased, 
respectively, in the temporal cortex in relation to increased AD-related neurofibrillary pathology. In 
vitro analysis revealed increased Aβ production after down-regulation of FRMD4A or ABCA7. 
Changes in tau phosphorylation were detected after down-regulation of FRMD4A or CD2AP. 
Finally, lentivirus-mediated DHCR24 overexpression was found to protect mouse primary cortical 
neurons from death upon induction of neuroinflammation in coculture with BV2 microglia. The 
protective effect was not mediated via activation of Akt/ERK survival signaling pathways, reduced 
production of nitric oxide or inflammatory cytokines or decreased caspase-3 activation. In conclusion, 
the data in this thesis suggest that increased DHCR24 levels might be protective in AD. In addition, 
LRP1 is involved in several different aspects of Aβ clearance, and the promotion of these clearance 
activities might be beneficial in AD. 
Collectively, this thesis provides new information on the role AD-related risk genes in the 
pathogenesis of AD. These findings might enable the development of novel treatment strategies for 
AD in the future. 
 
National Library of Medicine Classification: WT 155, QU 475, QU 477, QU 500, QU 550.5.G4 
Medical Subject Headings: Alzheimer disease/genetics; Gene Expression; Transcriptome; Genetic 
Variation; Multifactorial Inheritance; Risk Factors; Genes; Genetic Loci; Alleles; Biological Markers; 
Cerebrospinal Fluid; Inflammation; Brain; Neuroprotective Agents; Polymorphism, Single 
Nucleotide 
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TIIVISTELMÄ:  
 
Alzheimerin tauti (AT) on dementiaa aiheuttava etenevä hermoston rappeumasairaus. Tärkeimmät 
neuropatologiset löydökset AT:ssa ovat aivoihin kertyvät β-amyloidipeptidistä (Aβ) koostuvat plakit 
sekä hyperfosforyloituneesta tau-proteiinista muodostuvat neurofibrillikimput. Muita keskeisiä 
piirteitä AT:ssa ovat hermopäätteiden ja hermosolujen tuhoutuminen sekä aivoissa vallitseva 
tulehdus. Geneettiseltä pohjaltaan AT on monimuotoinen, ja nykyään tunnetaan yli 20 geneettistä 
varianttia, jotka vaikuttavat yksilön riskiin sairastua AT:iin, mutta näiden varianttien toiminnalliset 
mekanismit AT:n patogeneesissä tunnetaan huonosti. AT:iin on tällä hetkellä tarjolla ainoastaan 
oireenmukaista hoitoa, eikä tautia ole mahdollista estää tai sen etenemistä pysäyttää. AT:n 
patogeneesin parempaan tuntemukseen tähtäävät tutkimukset ovatkin ensiarvoisen tärkeitä, sillä ne 
mahdollistavat uusien hoitokeinojen kehittämisen.  
Tämän väitöstutkimuksen tavoitteena oli selvittää AT:n geneettisten riskitekijöiden yhteyttä AT:n 
patogeneesiin sekä arvioida DHCR24- ja LRP1-proteiinien roolia AT:n lääkehoidon kohteena. 
Geneettiset riskivariantit SLC24A4- ja EPHA1-geeneissä olivat yhteydessä Aβ:n määrään, ja FERMT2-
geenin riskivariantti oli yhteydessä tau-proteiinin tasoihin AT-potilaiden aivo-selkäydinnesteessä, 
mutta tulokset eivät olleet tilastollisesti merkitseviä korjausten jälkeen. Polygeeninen riskiarvo, joka 
yhdistää 22 AT:n riskivarianttia oli yhteydessä Aβ:n määrään sekä aivo-selkäydinnesteessä että 
ohimoaivokuorella. Polygeeninen riskiarvo korreloi Aβ:n tuotantoon osallistuvan γ-
sekretaasientsyymin aktiivisuuteen ohimoaivokuorella ainoastaan kun voimakkain geneettinen 
riskitekijä APOE poistettiin riskiarvosta. Tutkittaessa riskigeenien ilmentymistä ohimoaivokuorella 
havaittiin lisääntynyt MS4A6A:n ja vähentynyt FRMD4A:n ilmentyminen lisääntyneen 
neurofibrillipatologian mukaan. In vitro-tutkimukset osoittivat Aβ:n tuotannon kasvavan, kun 
FRMD4A- ja ABCA7-proteiinitasoja laskettiin. Tau-proteiinin fosforylaatiossa havaittiin muutoksia 
FRMD4A- ja CD2AP-proteiinitasojen laskemisen seurauksena. 
Lentivirusvälitteinen DHCR24-geenin yli-ilmentäminen suojasi hiiren aivokuoren 
primäärihermosoluja neuroinflammaation aiheuttamalta solukuolemalta yhteisviljelmässä BV2-
mikrogliasolujen kanssa. Suojaava vaikutus ei ollut yhteydessä typpioksidin tai tulehdusta lisäävän 
sytokiinin tuotantoon, kaspaasi-3:n aktivaatioon tai Akt ja ERK-signalointireittien 
aktiviteettimuutoksiin. Saatujen tulosten perusteella DHCR24:n ilmentymisen nostaminen voisi olla 
hyödyllistä AT:n hoidossa. LRP1 osallistuu Aβ:n poistamiseen aivoista usealla tavalla, ja näiden 
toimintojen edistäminen saattaa olla hyödyllistä AT:n hoidossa. 
Yhteenvetona, tämä väitöskirja tarjoaa uutta tietoa geneettisten riskitekijöiden osuudesta AT:n 
patogeneesissa. Nämä löydökset voivat tulevaisuudessa avata tietä uudenlaisten AT:n hoitokeinojen 
kehittämiselle. 
 
 
Luokitus: WT 155, QU 475, QU 477, QU 500, QU 550.5.G4 
Yleinen Suomalainen asiasanasto: Alzheimerin tauti; geenit; geeniekspressio; geneettinen muuntelu; 
periytyvyys; riskitekijät; markkerit; aivo-selkäydinneste; tulehdus; aivot 
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 1 Introduction  
Alzheimer’s disease (AD) is the leading cause of dementia among the elderly, estimated to 
affect 24 million people worldwide. The prevalence of AD rises steeply after 65 years of age, 
nearly doubling every 5 years and leading to over 25% prevalence in individuals over 90 
years (Qiu et al. 2009). Clinical manifestations of AD typically start with impairment of 
episodic memory, followed by progressive weakening of most of the cognitive functions and 
eventually leading to an inability towards self-care and a complete loss of independent living 
(McKhann et al. 2011). Thus, AD is a significant burden not only to the affected individual, 
but also to family members and caregivers. Currently, only symptomatic treatment for AD is 
available and it is not possible to intervene with the inevitable progression of the disease. 
The neuropathological hallmarks of AD are senile plaques composed of amyloid-β (Aβ) 
peptide and neurofibrillary tangles (NFTs) composed of hyperphosphorylated protein tau 
(Hardy et al. 2002a). Aβ is produced from amyloid precursor protein (APP) by a sequential 
proteolytic cleavage, and an imbalance between the production and clearance of Aβ leads to 
its accumulation within the brain. Accumulation of Aβ begins years before the onset of 
clinical symptoms, and is believed to function as a seed, initiating harmful downstream 
effects such as formation of NFTs, synaptic and neuronal loss, as well as neuroinflammation 
due to activation of microglia and astrocytes.  
Two forms of AD can be distinguished based on the genetic background. Rare familial 
early-onset AD (EOAD) is caused by autosomal, dominantly inherited mutations in APP, 
PSEN1, and PSEN2 genes, which affect the production of Aβ (Goate et al. 1991, Levy-Lahad 
et al. 1995, Rogaev et al. 1995, Sherrington et al. 1995). The more common late-onset form has 
a more heterogeneous genetic background, with several genetic polymorphisms affecting an 
individual’s risk of developing AD together with non-genetic factors.  Apolipoprotein E 
(APOE) ε4 allele has long been established as a major genetic risk factor contributing to late-
onset AD (LOAD) (Corder et al. 1993, Strittmatter et al. 1993). Recently, large-scale genome-
wide association studies (GWASs) have identified over 20 common genetic variants across 
the genome that increase or decrease the risk of AD (Harold et al. 2009, Hollingworth et al. 
2011, Lambert et al. 2009, Lambert et al. 2013b, Naj et al. 2011). However, the functional 
relevance of the genetically identified risk variants, as well as the events triggering and 
contributing to the pathogenic cascades in AD, are poorly understood.  
Better understanding of the mechanisms underlying the pathogenesis of AD is pivotal, as 
it provides opportunities for developing urgently needed therapeutic interventions. The aim 
of this thesis was to investigate the potential roles of genetic AD risk variants by assessing 
their associations with AD-related Aβ- and NFT-pathology within the brain and 
cerebrospinal fluid (CSF) and the expression of the associated genes in the temporal cortex. 
Furthermore, the potential of DHCR24 and LRP1 proteins as possible therapeutic targets in 
treatment of AD was evaluated in this thesis. 
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2 Review of the literature 
2.1 CLINICAL AND NEUROPATHOLOGICAL CHARACTERIZATION OF 
ALZHEIMER’S DISEASE 
AD is a progressive neurodegenerative disease and the most common cause of dementia. The 
first symptom and the clinical hallmark of AD is typically (in 86–94% of cases) the 
impairment of episodic memory, more specifically difficulty in learning and remembering 
new information (Dubois et al. 2007, Dubois et al. 2014, McKhann et al. 2011). Along with the 
progression of the disease, other forms of cognitive dysfunction start to appear, including 
worsening of linguistic abilities, deficits in spatial cognition and impaired face recognition, 
as well as impaired reasoning, judgment and problem solving (McKhann et al. 2011). 
Eventually the decline of multiple cognitive functions leads to loss of independence and 
inability to take care of oneself.  
Different sets of criteria for the diagnosis of AD have been developed, such as The National 
Institute on Neurological and Communicative Disorders and Stroke and the Alzheimer 
Disease and Related Disorders Association (NINCDS-ADRDA, McKhann et al. 1984), and 
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, American Psychiatric 
Association 2000). Both criteria require initial diagnosis of dementia, after which AD can be 
assigned as the probable cause based on the clinical features. According to NINCDS-
ADRDA, a definitive diagnosis of AD can be obtained only post-mortem, if the 
histopathological evidence supports the clinical diagnosis. 
With advancing knowledge of the biological basis of AD, increasing effort has been put on 
to redefine and improve the diagnostic criteria, especially to better recognize the earlier 
stages of the AD pathology before the onset of dementia symptoms. These include the 
International Working Group (IWG) for New Research Criteria for the Diagnosis of AD 
(Dubois et al. 2007), IWG-2 (Dubois et al. 2014), and the National Institute on Aging–
Alzheimer’s Association criteria (NIA-AA) (Jack et al. 2011). These new criteria retain the 
impairment of episodic memory as the core element, but also include CSF or imaging 
biomarker evidence in the diagnostic process to facilitate earlier diagnosis as well as increase 
the specificity to differentiate AD and AD-related pathophysiological processes from other 
possible causes of pathology and dementia, such as vascular dementia, dementia with Lewy 
bodies, and frontotemporal lobar degeneration (FTLD) (Dubois et al. 2014, Jack et al. 2011). 
Earlier and more accurate diagnosis is instrumental in attempts for earlier intervention before 
irreversible pathological injury occurs, and also in recruiting at-risk individuals to clinical 
trials, where conversion to AD is often used as an endpoint and thus where inclusion of 
individuals with non-AD related pathologies might confound the results. 
Before the manifestation of the clinical symptoms, the neuropathological features of AD 
have been developing over the preceding years. The neuropathological hallmark lesions of 
AD are NFTs composed of aberrantly misfolded and abnormally hyperphosphorylated 
microtubule-associated protein tau and neuritic plaques composed of Aβ peptide 
(Duyckaerts et al. 2009). Other neuropathological features include synaptic and neuronal 
loss, and neuroinflammation due to astrogliosis and microglial activation. 
3 
 
 
Amyloid plaques are found throughout the cortex in individuals with AD (Arnold et al. 
1991, Thal et al. 2002). Morphological evaluation and staining with dyes such as Thioflavin-
S and Congo Red which specifically detect the β-pleated sheet conformation can be used to 
differentiate dense-core or neuritic plaques from diffuse plaques. The neuritic plaques seem 
to be deleterious as they associate with dystrophic neurites and synapse loss and are 
surrounded by activated astrocytes and microglia, and are often found in individuals with 
AD (Serrano-Pozo et al. 2011a). Diffuse plaques, on the other hand, are relatively common in 
individuals with no evidence of cognitive impairment and they lack the deleterious 
associations detected in the case of the neuritic type (Serrano-Pozo et al. 2011a). 
NFTs are primarily found in limbic and association cortices (Arnold et al. 1991, Braak et 
al. 1991). The spread of NFT pathology has a distinct spatiotemporal pattern that can be 
divided to six stages, starting from the entorhinal cortex and hippocampus of the medial 
temporal lobe (stages I-II, Figure 1), progressing to limbic structures (stages III-IV), and 
finally to isocortex (stages V-VI) (Braak et al. 1991, Braak et al. 2006). NFT pathology 
correlates with the severity of the cognitive decline, duration of dementia and the hierarchical 
neuropsychological profile of AD dementia (Arriagada et al. 1992, Bierer et al. 1995, 
Giannakopoulos et al. 2003, Gomez-Isla et al. 1997, Ingelsson et al. 2004). Despite this clear 
synchrony between NFTs and AD symptoms, it has remained uncertain whether NFTs are 
causative or represent a mere casual associate of cognitive decline. 
 
 
Figure 1. Progression of the AD-related neurofibrillary pathology according to the six-stage Braak 
staging scale in coronal hemisphere sections immunostained for hyperphosphorylated tau. 
(Adapted from Braak et al., 2006, Acta Neuropathol 112:389–404, with kind permission of 
Springer Science and Business Media). 
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2.1.1 CSF and neuroimaging biomarkers 
Data from several studies suggests that biomarkers can improve the specificity or accuracy 
(or both) of a clinical AD diagnosis. Indeed, biomarkers are included in the latest diagnostic 
criteria for AD, where evidence of at least one abnormal CSF or imaging biomarker can be 
used to support the clinical diagnosis of AD (Dubois et al. 2014, Jack et al. 2011). Abnormal 
biomarker findings follow a distinct pattern, in which accumulation of Aβ is the first 
detectable change, followed by tau-related pathology and brain atrophy (Figure 2). Cognitive 
dysfunctions start to appear at a time when the amyloid pathology is full blown.  
 
 
 
Figure 2. Dynamics of AD-related biomarkers. Accumulation of Aβ precedes tau pathology, 
changes in brain structure and cognitive dysfunction by several years. (Adapted from Jack et al., 
2010, The Lancet Neurology 9:119–128, with the kind permission of Elsevier). 
 
Due to the direct contact with the extracellular space of the brain, CSF reflects the 
pathological alterations taking place in the AD brain. Both Aβ and tau can be quantified in 
the CSF, and the combination of Aβ42, phosphorylated tau (p-tau) and total tau (t-tau) CSF 
measurements can discriminate individuals with AD from non-demented controls with an 
accuracy and specificity of over 80% and thus provide better diagnostic accuracy than any of 
these biomarkers alone (Blennow 2004, Galasko et al. 1998, Hansson et al. 2006, Mattsson et 
al. 2009). CSF Aβ42 levels have been shown to be decreased by approximately 50% in 
individuals with AD, and this is thought to reflect the sequestration of Aβ into plaques, that 
consequently leaves less Aβ available for diffusion into the CSF (Blennow et al. 2012, 
Grimmer et al. 2009b, Sunderland et al. 2003). CSF Aβ42 levels have been found to negatively 
correlate with postmortem plaque loads (Strozyk et al. 2003, Tapiola et al. 2009) and in vivo 
Aβ load in the brain, detected with positron emission tomography (PET) (Fagan et al. 2006, 
Grimmer et al. 2009a, Tolboom et al. 2009). T-tau levels in the CSF of AD patients are 
increased by 300% compared to non-demented individuals, and reflect the intensity of 
neuronal degeneration (Sunderland et al. 2003). CSF p-tau in turn reflects the levels of tau 
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phosphorylation state and tangle formation in the brain (Blennow et al. 2012). CSF t-tau and 
p-tau (phosphorylated at either threonine 181 or 231) levels have been shown to correlate 
with post-mortem tangle load, faster cognitive decline and higher mortality among AD 
patients, as well as more rapid progression from mild cognitive impairment (MCI) to AD 
(Blom et al. 2009, Buerger et al. 2006, Samgard et al. 2010, Tapiola et al. 2009, Wallin et al. 
2009). Although the CSF biomarkers cannot perfectly discriminate AD from some other 
dementias such as Lewy body dementia or vascular dementia, due to overlapping pathology, 
they have been shown to identify prodromal AD among individuals with MCI with 95% 
sensitivity, and might thus be a valuable clinical tool (Hansson et al. 2006). 
In addition to CSF biomarkers, non-invasive imaging techniques can provide insights in 
the AD pathology in the brain. Magnetic resonance imaging (MRI), both structural and 
functional, and PET detecting cerebral metabolism and Aβ can reveal AD-related changes in 
the brain (Johnson et al. 2012). The first structural changes detected in MRI are atrophy in the 
entorhinal cortex, hippocampus, and amygdala (Dickerson et al. 2001, Killiany et al. 2002). 
The MRI volumes of brain regions have been shown to reflect the post-mortem neuronal 
counts, thus MRI provides an accurate method to visualize brain atrophy in relation to AD 
(Bobinski et al. 2000). Neuronal activity can be measured with functional MRI which detects 
alterations in blood oxygen levels, as increased brain activity uses more oxygen (Kwong et 
al. 1992, Ogawa et al. 1990). Decreased neuronal activity in the hippocampus has been 
reported in AD patients, reflecting the impairment in episodic memory (Rombouts et al. 2000, 
Sperling et al. 2003). Synaptic activity, on the other hand, can be measured with PET imaging 
detecting glucose metabolism. This method has been shown to have a high discriminative 
accuracy between probable AD and non-demented or non-AD dementia bearing individuals 
(Patwardhan et al. 2004). In addition, ligands binding to Aβ, such as Pittsburgh Compound 
B (PiB), have enabled visualization of Aβ levels in the brain with PET imaging, a measure 
shown to correlate with amyloid load detected post-mortem (Ikonomovic et al. 2008). 
2.2 MOLECULAR MECHANISMS RELATED TO AD PATHOGENESIS 
2.2.1 Amyloid-β production and clearance 
At the molecular level, Aβ is produced by sequential proteolytic cleavage of APP. APP is a 
large type I transmembrane protein alternatively spliced to produce several different 
isoforms. APP695 is the major isoform expressed in the brain (Kang et al. 1987), whereas 
APP770 and APP751 are the major non-neuronal isoforms expressed in multiple organs and 
tissues including the heart, lungs, kidney and muscles (Puig et al. 2013). APP has been 
reported to have diverse roles in different processes such as neuronal migration during 
embryonic development (Young-Pearse et al. 2007), formation and maintenance of synapses 
and neuromuscular junctions (Kamenetz et al. 2003, Loffler et al. 1992), neuronal maturation 
and differentiation (Hung et al. 1992) as well as intracellular signaling and transcription (Cao 
et al. 2004).  
APP is processed through two proteolytic cleavage pathways referred to as the 
amyloidogenic and non-amyloidogenic pathways depending on whether the cleavage 
results in the release of intact Aβ domain or not (Figure 3). The majority of the APP processing 
occurs via the non-amyloidogenic pathway, where α-secretase activity initiates the 
processing by cleaving APP in Aβ domain at the plasma membrane (Asai et al. 2003, Esch et 
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al. 1990, Postina et al. 2004, Sisodia et al. 1990), leading to the release of soluble APPα (sAPPα) 
into the extracellular space whereas the C-terminal fragment (CTF), known as C83, remains 
anchored into the membrane. The α-secretase cleavage is executed by members of a 
disintegrin and metalloprotease (ADAM) protease family, including ADAM10, ADAM17, 
ADAM9 and ADAM19, with ADAM10 being the predominant α-secretase in the brain (Kuhn 
et al. 2010).  
 
Figure 3. Non-amyloidogenic and amyloidogenic APP processing pathways. (Reproduced with 
permission from Querfurth & LaFerla, 2010, New England Journal of Medicine 362:329–344. 
Copyright Massachusetts Medical Society). 
 
The amyloidogenic pathway is initiated by β-secretase cleavage by an enzyme known as 
β-site APP cleaving enzyme (BACE1) (Vassar et al. 1999). BACE1 is a transmembrane aspartyl 
protease that is optimally functional in acidic intracellular compartments. Thus, BACE1-
mediated processing of APP takes place in the endosomes or trans-Golgi network (TGN) 
after internalization of APP from the cell surface (Haass et al. 1992, Vassar et al. 1999). Site-
specific cleavage of APP by BACE1 produces a membrane-bound CTF called C99 containing 
the Aβ domain, and sAPPβ is released into the endosomal or TGN lumen. 
Following the α- or β-secretase cleavage, C83 and C99 are further cleaved by γ-secretase, 
which is a protein complex consisting of four subunits: a presenilin (PS1 or PS2) as the 
catalytic subunit, accompanied by nicastrin (NCT), presenilin enhancer-2 (PEN-2) and 
anterior pharynx-defective (APH-1) (De Strooper et al. 1998, Edbauer et al. 2003). γ-secretase 
cleavage results in the release of the APP intracellular domain (AICD) into the intracellular 
compartment, and p3 or Aβ peptide into the extracellular compartment. Unlike β-secretase, 
γ-secretase cleavage is heterogeneous and leads to formation of Aβ peptides of 37–43 amino 
acids in length. The major form generated is Aβ40, whereas the more neurotoxic form Aβ42 
is produced to a lesser extent (Sisodia et al. 2002). It has been shown that Aβ42 is more prone 
to oligomerization and aggregation than Aβ40 due to its hydrophobicity, and thus is central 
to AD pathogenesis (Blennow et al. 2006, Hardy et al. 2002b, Jarrett et al. 1993). 
Two major pathways are recognized for Aβ clearance in the brain: transport of intact Aβ 
across the blood-brain barrier (BBB) or degradation within the brain (Figure 4). Aβ efflux 
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across the BBB is mediated by low-density lipoprotein-receptor related protein 1 (LRP1) 
(Pflanzner et al. 2011, Sagare et al. 2012, Shibata et al. 2000, Zlokovic et al. 2010), and is 
discussed in more detail in chapter 2.2.1.1, along with other LRP1-mediated Aβ clearance 
mechanisms. Within the brain, soluble Aβ can be taken up by the resident immune cells, 
microglia, via micropinocytosis, and rapidly targeted to the lysosomes for degradation 
(Mandrekar et al. 2009). The soluble forms of Aβ are also sensitive to degradation by many 
proteases. Insulin-degrading enzyme (IDE) (Qiu et al. 1998) and neprilysin (NEP) (Iwata et 
al. 2000), are the major enzymes involved in extracellular and intracellular degradation of 
Aβ, respectively. Degradation by other proteases such as endothelin converting enzyme 1 
(ECE1), angiotensin converting enzyme (ACE), plasmin, matrix metalloprotease 9 (MMP9), 
and presequence peptidase (PreP) have also been reported (Falkevall et al. 2006, Mukherjee 
et al. 2002, Soto et al. 1996). Fibrillar forms of Aβ are taken up by the microglia through 
receptor-mediated phagocytosis, but degradation of the fibrillar forms might be possible only 
when the microglia are activated (D'Andrea et al. 2004, Frautschy et al. 1998, Koenigsknecht 
et al. 2004, Majumdar et al. 2007). 
 
 
Figure 4. Aβ clearance pathways within the central nervous system. Low-density lipoprotein 
receptor-related protein 1 (LRP1) mediates the clearance of Aβ across the blood-brain barrier to 
the vasculature, and uptake of Aβ into various cell types where it is targeted for lysosomal 
degradation. Enzymatic proteolysis of Aβ is carried out mainly by neprilysin (Nep) and insulin-
degrading enzyme (IDE). Abbreviations: α2M, α2-macroglobulin; APP, amyloid precursor protein; 
APOE, apolipoprotein E; MMP, matrix metalloproteinase; MOTC, microtubule-organizing center; 
MVB, multivesicular body; RAGE, receptor for advanced glycation end products. (Reproduced with 
permission from Querfurth & LaFerla, 2010, New England Journal of Medicine 362:329–344. 
Copyright Massachusetts Medical Society). 
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2.2.1.1 The role of LRP1 in APP processing 
LRP1 belongs to the family of low-density lipoprotein (LDL) receptors that when bound to 
extracellular ligands initiate intracellular signaling cascades or target the ligands for 
degradation or recycling (Bu 2009, Holtzman et al. 2012).  LDL receptor family members are 
involved in diverse cellular functions, ranging from cholesterol metabolism to intracellular 
transport, synaptic plasticity and neuronal development (Herz et al. 2006, May et al. 2003). 
Several studies have suggested that LRP1 is involved in the clearance of Aβ from the central 
nervous system (CNS) via three mechanisms: efflux across the BBB, cellular uptake followed 
by degradation, and peripheral clearance. Furthermore, AD-related proteins APP and 
apolipoprotein E (APOE) are among the ligands of LRP1, thus a role in the processing of APP 
has been suggested. APOE in turn seems to affect the Aβ clearance by LRP1. Interestingly, 
LRP1 is cleaved by α-, β- and γ-secretases, leading to the release of soluble LRP1 (sLRP1) 
which has been detected in plasma, as well as the brain and CSF, with decreased levels 
observed in AD patients (Liang et al. 2012, Liu et al. 2009, Lleo et al. 2005, Quinn et al. 1997, 
Sagare et al. 2007, von Arnim et al. 2005). 
The transport of molecules between the CNS and periphery is tightly regulated by the 
BBB, which is formed at cerebral microvessels by brain endothelial cells attached together 
with tight junctions (Abbott et al. 2006). Aβ is known to be transported across the BBB and 
several studies have supported the role of LRP1 as the major receptor for Aβ at the BBB 
(Pflanzner et al. 2011, Sagare et al. 2012, Shibata et al. 2000, Zlokovic et al. 2010) but some 
discrepancy remains as other studies have suggested no or only a minor involvement of LRP1 
(Ito et al. 2006, Ito et al. 2010, Nazer et al. 2008). However, LRP1 alone might not be sufficient 
to mediate Aβ efflux across the BBB, as LRP1 is primarily an endocytic receptor and located 
on the abluminal side of BBB, and might therefore need a co-transporter on the luminal side 
of the BBB to complete the transcytosis (Cirrito et al. 2005, Hartz et al. 2010, Krieger et al. 
1994). A recent report elegantly demonstrated that Aβ binding to LRP1 recruited PICALM, 
which bound to the C-terminal YXXL motif of LRP1, and mediated interaction between Aβ-
LRP1 complex and small GTPase Rab5, which regulates vesicle fusion for early endosomes, 
and subsequently Rab11 which, in turn, regulates recycling of vesicles controlling 
transcytosis and exocytosis of ligands (Zhao et al. 2015). This finding is particularly 
interesting, as polymorphism in PICALM locus has been shown to associate with AD risk 
(Harold et al. 2009, Lambert et al. 2013b). 
LRP1 has been implicated in the internalization of Aβ mostly in neurons, but some studies 
have suggested a similar mechanism also in vascular smooth muscle cells and astrocytes 
(Fuentealba et al. 2010, Kanekiyo et al. 2012, Koistinaho et al. 2004) (Figure 4). Aβ alone or as 
a complex with other ligands such as ApoE has been shown to be internalized by LRP1, and 
directed for lysosomal degradation (Fuentealba et al. 2010, Gylys et al. 2003, Zerbinatti et al. 
2006). However, all Aβ internalized is not degraded but accumulates in the lysosomes, where 
the acidic pH favors aggregation of Aβ42 leading to cytotoxicity (Fuentealba et al. 2010, Ji et 
al. 2002, Ruzali et al. 2013, Wilhelmus et al. 2007, Zerbinatti et al. 2004). ApoE might have an 
isoform-specific effect on Aβ clearance via LRP1 so that lysosomal trafficking of Aβ is more 
efficient in ApoE3 than in ApoE4 expressing cells (Li et al. 2012). Furthermore, ApoE4 might 
aggravate the toxic effects of Aβ accumulation in the lysosomes (Belinson et al. 2008, Ji et al. 
2002, Ji et al. 2006). 
Another interesting, yet relatively little studied, action of LRP1 is the so called peripheral 
sink of Aβ. Aβ is transported across the BBB to the plasma, where sLRP1 binds 70–90% of 
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free circulating Aβ under normal conditions (Sagare et al. 2007). Aβ bound to sLRP1 cannot 
be transported back to the CNS, and the complex is taken up and degraded mostly by the 
liver and to a lesser extent by the kidneys. This maintains the peripheral sink of Aβ and allows 
continuous clearance of Aβ from the brain (Deane et al. 2008b, Sagare et al. 2007). 
In addition to the clearance of Aβ, LRP1 has also been implicated in Aβ production via 
endocytosis of APP to the endocytic compartments where amyloidogenic processing takes 
place (Cam et al. 2005, Ulery et al. 2000, Zerbinatti et al. 2004). LRP1 can bind directly to 
Kunitz protease inhibitor (KPI) domain of APP (Cam et al. 2005, Knauer et al. 1996, Kounnas 
et al. 1995) or use cytoplasmic adaptor proteins such as Fe65 or RanBP9 (Klug et al. 2011, 
Lakshmana et al. 2008, Lakshmana et al. 2009, Pietrzik et al. 2002, Trommsdorff et al. 1998). 
However, the biological relevance of LRP1 on APP processing in the context of AD is 
questionable, as decreased levels of LRP1 in the brain of human subjects and AD model mice 
have been reported in normal aging and especially in AD (Deane et al. 2004, Donahue et al. 
2006, Kang et al. 2000, Shibata et al. 2000), suggesting that LRP1 is not involved with 
increased Aβ production in AD. Rather, these findings suggest that impaired LRP1-mediated 
Aβ clearance might have a role in AD pathogenesis. 
2.2.2 Tau hyperphosphorylation 
Tau protein is encoded by MAPT (microtubule-associated protein tau) gene. Alternative 
splicing produces six isoforms that are differentially expressed in the developing and mature 
CNS (Goedert et al. 1989). In the mature CNS, tau is mainly found in the axons, where it 
binds to the microtubules, helping to stabilize them and promotes their assembly. Tau 
binding to microtubules is regulated by the dynamics of phosphorylation by kinases and 
dephosphorylation by phosphatases (Brandt et al. 2005, Dolan et al. 2010, Iqbal et al. 2009). 
Kinases known to be involved in tau phosphorylation include glycogen synthase kinase-3β 
(GSK-3β), cyclin-dependent protein kinase-5 (CDK5), protein kinase A (PKA), and 
MAP/microtubule affinity-regulating kinase (MARK) (Drewes et al. 1997, Schneider et al. 
1999, Wagner et al. 1996). Aberrant hyperphosphorylation of tau observed in AD likely 
results from imbalanced function between kinases and phosphatases, and leads to 
detachment of tau from the microtubules. Tau is prone to self-aggregation and when 
detached from the microtubules it starts to form paired helical filaments (PHFs) which 
further aggregate to NFTs, whereas the microtubules become unstable (Mandelkow et al. 
2012).  
Tau pathology is not limited to AD, but associates with several other neurodegenerative 
diseases, collectively termed tauopathies, including FTLD (Hutton et al. 1998). Accumulating 
evidence from in vitro and in vivo studies supports the view of interconnection between Aβ 
and tau in AD pathogenesis, so that Aβ is needed to induce tau pathology, and tau is needed 
to mediate the toxic effects of Aβ (De Felice et al. 2008, Israel et al. 2012, Lewis et al. 2001, 
Gotz et al. 2001, Jin et al. 2011, Lloret et al. 2015, Stancu et al. 2014, Takashima et al. 1993, 
Zheng et al. 2002). 
2.2.3 Neuroinflammation 
Another central feature in AD pathology is neuroinflammation. Activated immune cells 
microglia (Haga et al. 1989) and astrocytes (Mrak et al. 1996) accumulate around the amyloid 
plaques (Akiyama et al. 2000, Itagaki et al. 1989, Letiembre et al. 2009, Pike et al. 1995, Vehmas 
et al. 2003). Recent evidence suggests that glial response is also related to the neurofibrillary 
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degeneration (Ingelsson et al. 2004, Serrano-Pozo et al. 2011b). Both microglia and astrocytes 
excrete inflammatory cytokines upon activation (Griffin et al. 1995, Tarkowski et al. 1999). 
The main cells involved in the neuroinflammation are microglia, which are phagocytic cells 
responsible for clearance of cellular debris and pathogens, and have a role in the uptake of 
and subsequent lysosomal degradation of Aβ (Kettenmann et al. 2011). Encounters with 
pathological triggers will lead to activation of microglia and initiation of an innate immune 
response. For instance, binding and engulfment of Aβ will lead to microglial activation, 
involving production of pro-inflammatory cytokines and chemokines (El Khoury et al. 2003, 
Paresce et al. 1996, Stewart et al. 2010). Under normal circumstances such an activation upon 
contact with pathological triggers is likely beneficial as the pathological changes are quickly 
resolved and microglia convert to an alternative activation state characterized by tissue 
repair and anti-inflammatory actions (Heneka et al. 2015). In AD, however, continuous 
exposure to Aβ, accumulating neuronal debris, and damaged neuronal DNA fragments 
might hinder the resolution of inflammation, leading to a chronic inflammation state and 
functional impairment of the microglia (Akiyama et al. 2000, Heneka et al. 2015, Krabbe et al. 
2013, Li et al. 2004, Weiner et al. 2002). 
Cytotoxic effects of neuroinflammation can be mediated via pro-inflammatory cytokines, 
caspases, nitric oxide (NO) or reactive oxygen species (ROS) produced by microglia (Bal-
Price et al. 2001, Choi et al. 2005, Heneka et al. 2015, Lee et al. 2004, Meda et al. 1995). For 
example, elevated levels of pro-inflammatory cytokine interleukin 1β are detected in AD 
brains, and increased risk for conversion to AD is detected amongst MCI subjects with 
simultaneously enhanced pro-inflammatory and decreased anti-inflammatory cytokine 
levels (Heneka et al. 2013, Tarkowski et al. 2003). Inducible nitric oxide synthase (iNOS) is 
upregulated in AD brains, leading to increased production of NO. High concentrations of 
NO are toxic to neurons and participate in post-translational modifications such as the 
nitration of Aβ at tyrosine 10, which accelerates the aggregation of Aβ and thus might initiate 
amyloid plaque formation (Butterfield et al. 2007, Kummer et al. 2011, Vodovotz et al. 1996). 
In addition, NADPH oxidase activity is upregulated in AD, leading to increased production 
of hydrogen peroxide, which can further drive microglial activation (Choi et al. 2012, 
Jekabsone et al. 2006). Finally, increased activation of caspases 3, 7, and 8 has been detected 
in the microglia of AD patients (Burguillos et al. 2011). 
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2.3 GENETICS OF AD 
AD can be divided into early onset (EOAD) and late onset (LOAD) forms based on the onset 
age with the cut-off age at 65 years. LOAD is the more common form, accounting for 
approximately 90% of all AD cases. Autosomal dominant, highly penetrable mutations in 
APP, PSEN1 and PSEN2 have been established in EOAD. The genetic component in LOAD 
is also strong with estimated 60–80% heritability (Gatz et al. 2006) but unlike EOAD, LOAD 
is a genetically complex disease, most likely resulting from interplay between several genetic 
and non-genetic factors (Figure 5).  
 
 
Figure 5. Schematic presentation of AD genetics. Rare mutations in PSEN1, PSEN2 and APP are 
causative of early-onset AD. Several common variants modulate the risk of late-onset AD with a 
small effect size. Variants in TREM2 and APOE have a medium to large risk effect. (Reproduced 
from Guerreiro et al., 2013, Cell 155:968, with the kind permission of Elsevier). 
2.3.1 Causative mutations in familial early-onset AD 
Genetic linkage studies in families with autosomal dominant inheritance pattern of AD 
resulted in the identification of mutations in three genes: APP, PSEN1 and PSEN2 (Presenilin 
1 and 2) (Goate et al. 1991, Levy-Lahad et al. 1995, Rogaev et al. 1995, Sherrington et al. 1995). 
Virtually all the identified mutations in these three genes influence the processing of APP so 
that the ratio of the more pathogenic Aβ42 to Aβ40 is increased (Scheuner et al. 1996). Whole-
gene duplication of APP leads to overall increase in Aβ levels and has been identified as a 
cause of familial AD (Rovelet-Lecrux et al. 2006). Furthermore, individuals with trisomy 21 
(otherwise known as Down syndrome) have an additional copy of APP due to the 
duplication of the whole chromosome 21 and affected individuals exhibit AD-like 
neuropathology (Oyama et al. 1994). To date, 33, 185 and 13 individual mutations in APP, 
PSEN1 and PSEN2, respectively, have been reported as causes of familial early-onset AD 
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(www.molgen.vib-ua.be/ADMutations). It is noteworthy, however, that the mutations in 
APP, PSEN1 and PSEN2 are responsible for only approximately 1% of all AD cases and 13% 
of EOAD cases (Bekris et al. 2010, Campion et al. 1999), thus mutations in other genes are 
likely to be involved in EOAD. 
2.3.2 Risk genes in late-onset AD 
The ε4 allele of APOE gene was established as a genetic risk factor for AD as early as in the 
1990s (Corder et al. 1993, Strittmatter et al. 1993) and remains to date the strongest known 
one, increasing the risk 3-fold in the carriers with one copy of ε4 allele, and 15-fold in the 
carriers of two copies (Farrer et al. 1997). The hunt for AD risk genes continued with 
candidate gene approach, where previous knowledge of the gene and its functions was used 
as selection criteria, and polymorphisms within the gene were assessed for association with 
AD. Candidate gene studies have resulted in over 700 genes being reported to associate with 
AD, however, the replicability of these findings in independent cohorts has been usually 
poor. Advances in technology have allowed genome-wide association studies (GWAS) to be 
performed, where millions of single-nucleotide polymorphisms (SNPs) can be evaluated 
simultaneously in thousands of individuals (Wray et al. 2008). To date, GWASs, comparing 
SNP genotype frequencies between thousands of AD cases and elderly non-demented 
controls, have identified over 20 loci that associate with risk of developing AD (listed in Table 
1, Harold et al. 2009, Hollingworth et al. 2011, Lambert et al. 2009, Lambert et al. 2013b, Naj 
et al. 2011, Seshadri et al. 2010). Furthermore, an AD susceptibility locus was identified 
within the FERM domain containing 4A (FRMD4A) gene by a genome-wide haplotype 
association study (Lambert et al. 2013a). Rare coding variants have been identified with 
whole genome or whole exome sequencing approaches in the triggering receptor expressed 
on myeloid cells 2 (TREM2) gene (increasing the AD risk) (Guerreiro et al. 2013a, Jonsson et 
al. 2013) and in the APP gene (decreasing the risk) (Jonsson et al. 2012). The SNPs identified 
in GWASs do not necessarily have functional relevance themselves, but might be in linkage 
disequilibrium (LD) with the true functional variants and thus act as markers of the real 
genetic locus (Hindorff et al. 2009). Targeted re-sequencing of the loci can be used to identify 
the possible functional variants, and recent efforts have identified rare functional variants 
within GWAS-identified ABCA7, CD2AP, EPHA1, and BIN1 loci (Steinberg et al. 2015, 
Vardarajan et al. 2015). 
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Table 1. Polymorphisms reported for association with AD risk in meta-analyses of GWAS datasets 
and their respective odds ratios 
 
Polymorphism Chromosomal 
position 
Gene 
symbol 
Gene/protein name OR (95% CI) 
AlzGene top10 
ε2/ ε3/ ε4 19q13.2 APOE Apolipoprotein E 3.69 (3.30–4.12) 
rs744373 2q14 BIN1 Bridging integrator 1 1.17 (1.13–1.20) 
rs11136000 8p21–p12 CLU Clusterin/ Apolipoprotein J 0.88 (0.86–0.90) 
rs3764650 19p13.3 ABCA7 ATP-binding cassette, subfamily A, 
member 7 
1.23 (1.18–1.28) 
rs3818361 1q32 CR1 Complement receptor 1 1.17 (1.14–1.21) 
rs3851179 11q14 PICALM Phosphatidylinositol-binding clathrin 
assembly protein 
0.88 (0.86–0.9) 
rs610932 11q12.1 MS4A6A Membrane-spanning 4-domains, 
subfamily A, member 6A  
0.90 (0.88–0.93) 
rs3865444 19q13.3 CD33 CD33 molecule/ myeloid cell surface 
antigen CD33 
0.89 (0.86–0.93) 
rs670139 11q12.1 MS4A4E membrane-spanning 4-domains, 
subfamily A, member 4E 
1.08 (1.05–1.11) 
rs9349407 6p12 CD2AP CD2 associated protein 1.12 (1.08–1.16) 
Lambert et al. 2013b 
rs11771145 7q34 EPHA1 EPH receptor A1 0.90 (0.88–0.93) 
rs9271192 6p21.3 HLA-DRB5 Major histocompatibility complex, 
class II, DR beta 5 
1.11 (1.08–1.15) 
rs28834970 8p21.1 PTK2B Protein tyrosine kinase 2 beta 1.10 (1.08–1.13) 
rs11218343 11q23.2-q24.2 SORL1 sortilin-related receptor, L(DLR 
class) A repeats containing 
0.77 (0.72–0.82) 
rs10498633 14q32.12 SLC24A4 Solute carrier family 24, member 4 0.91 (0.88–0.94) 
rs8093731 18q12.1 DSG2 Desmoglein 2 0.73 (0.62–0.86) 
rs35349669 2q37.1 INPP5D Inositol polyphosphate-5-
phophatase 
1.08 (1.05–1.11) 
rs190982 5q14.3 MEF2C Monocyte enhancer factor 2C 0.93 (0.90–0.95) 
rs2718058 7p14.1 NME8 NME/NM23 family member 8 0.93 (0.90–0.95) 
rs1476679 7q22.1 ZCWPW1 Zinc finger, CW type with PWWP 
domain 1 
0.91 (0.89–0.94) 
rs10838725 11p11 CELF1 CUGBP, Elav-like family member 1 1.08 (1.05–1.11) 
rs17125944 14q22.1 FERMT2 Fermitin family member 2 1.14 (1.09–1.19) 
rs7274581 20q13.31 CASS4 Cas scaffolding protein family 
member 4 
0.88 (0.84–0.92) 
Adapted from www.alzgene.org/TopResults.asp and Lambert et al. 2013 Nature Genetics 45:1452–1458. 
Abbreviations: OR, odds ratio; CI, confidence interval. 
 
Some GWAS findings have confirmed candidate gene findings (e.g. CLU, SORL1) whereas 
others have brought attention to new genomic locations. As mentioned above, over 20 genetic 
loci have been implicated in GWA studies, with a few additional loci or genes identified in 
genome-wide haplotype studies or with whole-genome sequencing. It is customary to report 
the SNP together with the closest gene in the GWA studies, however it should be 
remembered that some of the genome-wide significant SNPs mark a locus with several genes, 
thus the identification of the truly affected gene is not always straightforward. Furthermore, 
especially the SNPs located in intergenic regions might be involved in the regulation of gene 
expression, and such regulatory elements might extend their effects on genes many 
thousands of kilobases away on the same chromosome or even on entirely different 
chromosomes (Nica et al. 2013). 
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2.4 MOLECULAR MECHANISMS OF AD-ASSOCIATED GENES  
Elucidation of the functional roles of the risk variants is important in order to better 
understand the mechanisms leading to AD and to be able to develop new treatment strategies 
to intervene with the disease onset and progression. Several different methods are applied to 
reveal the functional mechanisms of the disease-associated variants and genes, including 
gene expression studies, correlations with Aβ and tau levels or AD-associated 
endophenotypes such as cognitive performance, neuroimaging traits or age at onset, and 
studies with different disease models (Figure 6) (Bettens et al. 2013).  
 
Figure 6. Identification of genetic associations and types of functional studies that can be used to 
reveal underlying biological processes or pathways (Adapted from Bettens et al., 2013, The Lancet 
Neurology 12:92–104, with kind permission of Elsevier). Abbreviations: CSF, cerebrospinal fluid; 
AD, Alzheimer’s disease; iPSC, induced pluripontent stem cell. 
Some common pathways or biological processes are found among the genes within 
GWAS-identified loci, including Aβ clearance, endocytosis, lipid metabolism, immune 
functions, focal adhesions, synaptic functions, and regulation of transcription or RNA 
splicing (Figure 7A). The classification is not often clear, as the same gene might have diverse 
functions and thus belong to multiple groups. Another way to classify these genes is based 
on their associations with Aβ and tau in patient material or in functional studies in disease 
models (Figure 7B). 
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Figure 7. Functional classification of AD-associated genes. A) The pathways in which the AD-
associated genes are enriched. Due to the multiple functions a single gene may have, many of 
these genes can be designated into more than one functional group. B) Classification based on 
reported associations with the neuropathological hallmarks of AD, Aβ and tau. Genes falling into 
the category with no reported associations are mainly due to lack of studies, however at least one 
study has assessed EPHA1 but detected no association. 
2.4.1 Aβ clearance 
Accumulation of Aβ is a central event in AD pathogenesis, and in LOAD it is thought to be 
mainly a result of impaired clearance rather than increased production (Hardy et al. 2002a). 
APOE and clusterin (also known as ApoJ), the protein products of APOE and CLU, 
respectively, bind to Aβ and might promote its clearance or aggregation. Complement 
component receptor CR1 can clear C3b-bound Aβ42 from the circulation, whereas ABCA7, 
CD33 and TREM2 are involved with the microglial phagocytosis of Aβ. 
2.4.1.1 APOE 
APOE has long been established as the strongest genetic risk factor for LOAD. APOE is 
expressed and translated into three isoforms differing at amino acid residues 112 and 158: 
APOE ε2 (Cys112, Cys158), APOE ε3 (Cys112, Arg158), and ε4 (Arg112, Arg158) (Mahley et 
al. 2000). APOE ε4 is the risk-conferring allele associated with increased prevalence of AD 
and earlier age of onset among the carriers (Corder et al. 1993, Bu 2009, Rebeck et al. 1993). 
APOE is found in the amyloid plaques, and more advanced plaque pathology is observed in 
APOE ε4 carriers (Kok et al. 2009, Namba et al. 1991, Polvikoski et al. 1995, Schmechel et al. 
1993). Amyloid plaque loads are APOE isoform-dependent (ε4 > ε3 > ε2), (Bales et al. 2009, 
Castellano et al. 2011, Reiman et al. 2009) and studies suggest that APOE ε4 impairs Aβ 
clearance or is less effective in mediating the clearance by microglia and across BBB than 
APOE ε3 and ε2 isoforms (Deane et al. 2008a, Jiang et al. 2008, LaDu et al. 1994). It has also 
been suggested that APOE might promote Aβ plaque formation in an isoform-dependent 
manner (Bales et al. 1997). APOE ε4 carriers (defined as having at least one allele) have greater 
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medial temporal atrophy, accelerated reduction in cortical thickness and hippocampal 
volume as compared to ε3 and ε2 carriers (Farlow et al. 2004, Fennema-Notestine et al. 2011, 
Korf et al. 2004). Increasing evidence suggests that APOE isoforms might also affect synaptic 
plasticity and repair, and dendritic spine density (Buttini et al. 2002, Chen et al. 2011, 
Dumanis et al. 2009, Ji et al. 2003, Wang et al. 2005). APOE genotype is associated with the 
levels of CSF biomarkers so that decreased levels of Aβ42 as well as increased levels of both 
t-tau and p-tau are detected among the ε4 carriers as compared to ε3 and ε2 carriers 
(Cruchaga et al. 2013, Galasko et al. 1998, Kauwe et al. 2010, Morris et al. 2010). 
2.4.1.2 CLU 
The role of clusterin (the protein product of CLU) in AD pathogenesis has been extensively 
studied since the original observation of increased CLU mRNA levels in the hippocampus of 
AD patients as compared to control individuals (May et al. 1992, Nuutinen et al. 2009). 
Several studies have since reported elevated CLU mRNA or protein levels in hippocampus, 
cortex, CSF, and plasma of AD patients (Karch et al. 2012, Lidstrom et al. 1998, Mullan et al. 
2013, Nilselid et al. 2006, Oda et al. 1994, Thambisetty et al. 2012). Increased levels of PiB 
binding have been detected in the entorhinal cortex of nondemented individuals with high 
plasma clusterin levels compared to those with lower levels (Thambisetty et al. 2012), and 
elevated brain atrophy was detected in the nondemented individuals with higher levels of 
CSF clusterin (Desikan et al. 2014). These recent findings suggest that clusterin might be used 
as an antecedent marker for AD. 
Higher CLU expression is detected in the brain than in other tissues, and within the brain 
CLU is highly expressed by astrocytes and neurons but by microglia at a low level (de Silva 
et al. 1990a, de Silva et al. 1990b, Jordan-Starck et al. 1994, Pasinetti et al. 1994). CLU 
expression is upregulated in response to stress or cellular injury, but also cell growth, 
differentiation and aging (May et al. 1992, Michel et al. 1997, Rosenberg et al. 1995, Trougakos 
et al. 2002). Clusterin is a multifunctional chaperone protein taking part in several cellular 
processes including apoptosis, proliferation and protein aggregation (Bailey et al. 2001, 
Calero et al. 2005, Lakins et al. 2002). Clusterin binds Aβ peptides and can either prevent or 
promote Aβ aggregation depending on the concentration, so that when Aβ levels rise over 
10-fold higher than those of clusterin, prevention switches to promotion of aggregation 
(Wilson et al. 2008, Yerbury et al. 2007). Clusterin can also promote the clearance of Aβ from 
the brain by binding it and mediating its transport across the BBB by LRP1 and LRP2 or 
directing it to microglia for phagocytosis (Bell et al. 2007, Nuutinen et al. 2009, Zlokovic et al. 
1996). The GWAS-identified SNP rs11136000 has been reported to associate with decreased 
plasma clusterin levels, changes in brain function and faster cognitive decline (Mengel-From 
et al. 2013, Schurmann et al. 2011, Thambisetty et al. 2013). Similarly, the SNP rs9331888 is 
also associated with decreased plasma clusterin levels and promotes alternative splicing of 
CLU (Szymanski et al. 2011, Xing et al. 2012).  
2.4.1.3 CR1 
SNPs rs6656401 and rs3818361 within CR1 locus increase the risk of AD. The CR1 gene 
encodes the complement receptor 1 protein which binds complement proteins C3b and C4b 
(Jacquet et al. 2013). CR1, acting as a major immune adherence molecule of erythrocytes, 
attenuates complement activation by clearing C3b/C4b-bound components from the 
circulation and transporting them to phagocytes in the liver and spleen (Brouwers et al. 2012). 
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C3b can bind Aβ42, and CR1-dependent clearance of Aβ42 from the circulation has been 
reported, thus CR1 might be linked to AD pathogenesis via this clearance activity in the 
circulation (Rogers et al. 2006). The finding that non-demented carriers of the rs6656401 SNP 
minor allele have a higher amyloid plaque burden than the non-carriers supports the idea 
that CR1 has a role in Aβ42 clearance (Chibnik et al. 2011). In the brain, CR1 expression was 
detected at low levels and only in white matter and cerebellum, which suggests that CR1 
might mainly function at systemic level or within brain vasculature (Holton et al. 2013). CR1 
is expressed in four isoforms differing in length, and in addition, variation between 
individuals is created at the expression level, known as density polymorphism. Recent 
studies suggest that the length and density polymorphisms might underlie the risk effect 
attributed to CR1 in AD, as the rs6656401 and rs3818361 were associated with expression of 
the alternative CR1*2 isoform (Brouwers et al. 2012, Mahmoudi et al. 2015). Although this 
isoform contains an additional C3b-binding site compared to the CR1*1 isoform, and could 
thus be expected to be more efficient in clearing Aβ42, it seems to be expressed at lower levels 
than the CR1*1 isoform. This situation might lead to impaired clearance of Aβ42 in 
individuals expressing the CR1*2 isoform, thus increasing the risk of AD (Brouwers et al. 
2012, Mahmoudi et al. 2015).  
2.4.1.4 ABCA7 
ABCA7 belongs to the ATP-binding cassette (ABC) transporter encoding gene superfamily, 
and its known functions include phagocytosis and efflux of phospholipids and cholesterol to 
apolipoproteins A-I and E (Abe-Dohmae et al. 2004, Wang et al. 2003, Iwamoto et al. 2006, 
Jehle et al. 2006). SNPs within the ABCA7 locus have been identified to associate with AD 
risk in GWASs, but the effect of these SNPs is not clear. Different studies have reported either 
increased, decreased, or unchanged expression of ABCA7 in relation to different SNPs (Allen 
et al. 2012, Karch et al. 2012, Vasquez et al. 2013). Interestingly, ABCA7 levels have been 
reported to increase in individuals with AD or cognitive decline (Karch et al. 2012, Vasquez 
et al. 2013). ABCA7 expression in the brain is highest in microglia (Kim et al. 2008). As knock-
out of ABCA7 in mice does not affect cholesterol efflux, but leads to increased Aβ 
accumulation, it has been suggested that the main role of ABCA7 is in phagocytosis of Aβ 
rather than in lipid metabolism (Kim et al. 2005, Kim et al. 2013). Recently discovered loss-
of-function mutations in ABCA7 increasing the risk of AD suggest that decreased levels of 
ABCA7 are harmful (Steinberg et al. 2015), consistent with the idea that ABCA7 is involved 
in Aβ clearance. Furthermore, increased methylation of CpG sites within the ABCA7 locus is 
associated with Aβ load and tau tangle density in a community-based cohort (Yu et al. 2015). 
2.4.1.5 CD33 
CD33 locus has been identified to associate with AD risk in GWASs, although this association 
was not replicated in the meta-analysis of four GWAS datasets (Lambert et al. 2013b). CD33 
is a member of sialic acid-binding immunoglobulin-like lectins (Siglecs), and in the brain it 
is expressed by microglia and neurons (Griciuc et al. 2013). CD33 mRNA and protein 
expression is increased in AD vs. control brain, most likely reflecting increased expression in 
microglia as no difference in the numbers of CD33-positive neurons was detected between 
control and AD brains (Griciuc et al. 2013, Karch et al. 2012). GWAS-identified SNPs 
rs3865444 and rs12459419, in LD with one another, are associated with exon 2 splicing 
efficiency in the human brain so that protective minor alleles promote exon 2 skipping and 
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to a lesser extent retention of intron 1 (Malik et al. 2015, Malik et al. 2013, Raj et al. 2014). 
These alterations both probably lead to non-functional CD33 protein, as exon 2 encodes IgV 
domain which is responsible for binding to sialic acid (Griciuc et al. 2013). . Another study 
has shown decreased CD33 protein levels in the homozygous carriers of the minor A allele 
in rs3865444, and suggesting that this SNP (or another SNP in LD to it) affects mRNA stability 
or translation efficiency of CD33 (Walker et al. 2015). Amyloid burden in the frontal cortex 
correlates with the number of CD33-positive microglia in AD brains (Griciuc et al. 2013). The 
full-length CD33 expressed in microglia inhibits phagocytosis of Aβ, whereas skipping of 
exon 2 promoted by the protective minor alleles does not inhibit the phagocytosis (Griciuc et 
al. 2013). Thus, the protective effect of CD33 variants is likely mediated via enhanced 
phagocytosis of Aβ. 
2.4.1.6 TREM2 
The rare, non-synonymous, variant R47H (rs75932628) in TREM2 gene was found to increase 
the risk of AD using combination of whole-genome and exome sequencing (Guerreiro et al. 
2013a, Jonsson et al. 2013). Attention was drawn to this genomic location, as it was implicated 
to nominally associate with AD risk in a meta-analysis of linkage results for late-onset AD 
(Butler et al. 2009). The same variant has also been implicated in FTLD, Parkinson’s disease 
(PD), and amyotrophic lateral sclerosis (Guerreiro et al. 2013b, Lattante et al. 2013, Rayaprolu 
et al. 2013). Previously, homozygous loss-of-function mutations in TREM2 were identified as 
a cause of Nasu-Hakola disease, a rare autosomal early-onset dementia, also known as 
polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (Paloneva 
et al. 2002). TREM2 is a type I transmembrane protein which forms a receptor-signaling 
complex with the TYRO protein tyrosine kinase-binding protein (TYROBP) and is thus 
involved in the activation of immune responses in macrophages and dendritic cells (Paloneva 
et al. 2002). In microglia, increased expression of TREM2 controls the reactive phenotype by 
enhancing phagocytic pathway and promoting the alternative (potentially protective) 
activation state, as well as by repression of inflammatory reactivity by suppressing the 
cytokine production and secretion (Frank et al. 2008, Piccio et al. 2007, Takahashi et al. 2007). 
TREM2 is expressed throughout the CNS with higher expression levels in white matter 
compared to other brain areas  (Guerreiro et al. 2013a), and TREM2 expression has been 
shown to increase simultaneously with increasing levels of Aβ in the cortex in mouse models 
of AD, suggesting a response to accumulation of Aβ (Guerreiro et al. 2013a, Neumann et al. 
2007). Recently, increased levels of TREM2 mRNA and protein were detected in the plasma 
of AD patients (Hu et al. 2014).  
2.4.2 Endocytosis and vesicular trafficking 
Endocytosis and vesicular trafficking within the cell are critical functions in AD pathogenesis 
as they might affect APP processing as well as synaptic activity and neurotransmitter release. 
AD risk genes involved in different aspects of endocytosis include BIN1, PICALM, CD2AP, 
SORL1 and FRMD4A. 
2.4.2.1 BIN1 
BIN1 has been implicated to associate with AD in several GWAS studies. SNPs within BIN1 
locus that have been found to increase the risk of AD include rs744373 and rs7561528 >28kB 
upstream of BIN1. No functional role for these SNPs has been confirmed, however, 
rs59335482, which is in LD with rs744373 and also upstream of BIN1, has been shown to 
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increase BIN1 expression (Chapuis et al. 2013). BIN1 belongs to the 
Bin1/amphiphysin/RVS167 gene family which is highly conserved through evolution from 
yeast to human, reflecting its important role in the cellular processes such as endocytosis, 
actin dynamics and membrane trafficking (Itoh et al. 2006). Due to its role in clathrin-
mediated endocytosis, a role in APP processing has been hypothesized (Di Paolo et al. 2002, 
Ramjaun et al. 1997, Wigge et al. 1998). However, siRNA silencing of BIN1 showed no effect 
on APP processing in human neuroblastoma SH-SY5Y cells (Glennon et al. 2013). On the 
contrary, an association with tau pathology has been established, as silencing of AMPH, the 
Drosophila homolog of BIN1, suppressed tau mediated neurotoxicity in Drosophila, and co-
localization and interaction between BIN1 and tau was detected in human neuroblastoma 
cell line and in mouse brain (Chapuis et al. 2013). 
2.4.2.2 PICALM 
PICALM is known to have a role in clathrin-mediated endocytosis and to mediate 
intracellular trafficking of endocytic proteins. PICALM has been implicated in several 
different aspects of the amyloidogenic pathway in AD. A screen in Saccharomyces cerevisiae 
strain W303 identified YAP1802, the PICALM homolog in yeast as a modulator of Aβ toxicity. 
Further characterization in the yeast, nematode, and rat cortical neurons suggested that 
PICALM is able to rescue the Aβ-induced deficits in clathrin-mediated endocytosis (Treusch 
et al. 2011). PICALM has also been shown to target APP CTFs for degradation in 
autophagosomes (Tian et al. 2013), and to be involved in clathrin-mediated endocytosis of γ-
secretase (Kanatsu et al. 2014). Decreased Aβ load has also been detected in APP-
overexpressing mice after silencing of Picalm (Xiao et al. 2012). Furthermore, a recent report 
utilizing in vitro BBB models and heterozygous Picalm knock-out mice demonstrated that 
PICALM has a role in the clearance of Aβ across the BBB (Zhao et al. 2015). LRP1 has been 
suggested as the major receptor for the clearance of Aβ across BBB (Pflanzner et al. 2011, 
Sagare et al. 2012, Shibata et al. 2000, Zlokovic et al. 2010). PICALM has been shown to bind 
the Aβ-LRP1 complex and to direct it towards the transcytotic pathway, instead of the 
direction of lysosomal degradation (Zhao et al. 2015). Interestingly, PICALM expression in 
the endothelial cells of brain microvessels, the anatomical constituents of BBB, was shown to 
be decreased in Braak stage V-VI individuals as compared to Braak stage I, indicating that 
clearance of Aβ across the BBB might be impaired in the later stages of AD (Zhao et al. 2015). 
Furthermore, the protective minor allele of the rs3851179 SNP was associated with increased 
PICALM mRNA and PICALM protein expression as well as increased Aβ clearance in 
endothelial cells derived from induced pluripotent stem cells (iPSC), suggesting that the 
protective effect of this SNP is due to enhanced Aβ clearance (Zhao et al. 2015). A role in 
regulating autophagy and tau clearance has also been suggested (Moreau et al. 2014). Finally, 
SNPs in PICALM have also been shown to correlate with entorhinal cortex thickness (Biffi et 
al. 2010, Furney et al. 2011). 
2.4.2.3 CD2AP 
The CD2AP protein is involved in vesicular trafficking and cytoskeletal reorganization 
(Dustin et al. 1998). SNPs rs9296559, rs9349407, and rs10948363 associate with an increased 
risk of AD, but their functions are unclear. SNP rs9349407 associates with neuritic plaque 
burden in AD brains (Shulman et al. 2013). CD2AP expression has been reported to be 
unchanged in AD brain as compared to controls (Karch et al. 2012). Knock-down of 
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Drosophila CD2AP ortholog, Cindr, enhances tau toxicity (Shulman et al. 2014b), whereas 
knock-down of Cd2ap in N2A-APP695 cells led to reduced levels of both Aβ40 and Aβ42, and 
to reduced ratio of Aβ42/40 in the cell culture medium (Liao et al. 2015). This coincided with 
decreased levels of APP on the cell membrane. However, silencing of Cd2ap in PS1APP 
transgenic mouse did not affect the absolute levels of Aβ, but instead, reduced the ratio of 
Aβ42/40. It might be, that CD2AP affects different aspects of Aβ homeostasis in different cell 
types. For example, expression knock-down in neurons might lead to decreased endocytosis 
of APP and thus reduced production of Aβ, whereas diminished levels in astrocytes and/ or 
microglia might lead to decreased Aβ clearance (Liao et al. 2015). CD2AP has also been 
implicated as a critical regulator of vesicular trafficking to the lysosome and therefore may 
play a role in degradation of Aβ (Cormont et al. 2003). 
2.4.2.4 SORL1 
The SORL1 gene, that encodes the sortilin-related receptor, had been implicated in AD 
pathogenesis well before its identification in the recent meta-analysis as a LOAD risk factor, 
as decreased expression of SORL1 was detected in AD patients and individuals with MCI 
(Sager et al. 2007, Scherzer et al. 2004). A later study did not find any difference in SORL1 
mRNA levels between AD and control brain (Sager et al. 2012). SORL1 is expressed in the 
neurons of cortex, hippocampus and cerebellum (Motoi et al. 1999). SORL1 has a direct link 
to AD pathogenesis, since it is a receptor directing APP for recycling in the endocytic 
pathway (Rogaeva et al. 2007). Within the cells, SORL1 is rapidly internalized from the 
plasma membrane to early endosomes, then retrogradely transported to TGN, and thereafter 
keeps shuttling between the TGN and early endosomes (Jacobsen et al. 2001, Nielsen et al. 
2007, Schmidt et al. 2007). APP bound to SORL1 is then either retained within the TGN or 
recycled between TGN and early endosomes, which prevents the secretase-mediated 
cleavage of APP and thereby both amyloidogenic and non-amyloidogenic processing of APP 
(Andersen et al. 2005, Herskowitz et al. 2012, Fjorback et al. 2012, Offe et al. 2006, Schmidt et 
al. 2007, Schmidt et al. 2012). Recently, the methylation status of certain CpG sites within 
SORL1 locus have been shown to associate with Aβ load, tangle density, and pathological 
AD diagnosis in a community-based cohort (Yu et al. 2015). Sorl1-deficient mice have 
increased Aβ levels (Dodson et al. 2008). Some SNPs within SORL1 are associated with 
decreased CSF Aβ levels (Guo et al. 2012, Kolsch et al. 2008). In addition, associations with 
CSF tau and hippocampal atrophy have been reported (Guo et al. 2012, Louwersheimer et al. 
2015), whereas some studies have failed to detect associations between SORL1 SNPs and CSF 
biomarkers (Elias-Sonnenschein et al. 2013). 
2.4.2.5 FRMD4A 
FRMD4A gene was identified as a risk factor for AD in a genome-wide haplotype association 
study. The function of FRMD4A in the brain is not well known, however its role in the 
activation of ADP ribosylation factor 6 (ARF6) described in endothelial cells might provide 
insights on its function within the CNS. ARF6 regulates actin cytoskeleton dynamics as well 
as non-clathrin mediated endocytosis and membrane trafficking, processes, which in the 
CNS, are crucial for neuronal development, synaptic transmission and synaptic plasticity. 
ARF6 is activated via guanine nucleotide exchange factors (GEFs). In the endothelial cells, 
FRMD4A was found to mediate interaction between Par-3, a member of PAR protein 
complex involved in polarization of adherens junctions, and cytohesin-1, functioning as 
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ARF6 GEF in the endothelial cells, and the resulting Par-3/FRMD4A/cytohesin-1 complex 
was proposed to regulate the accurate activation of ARF6 (Ikenouchi et al. 2010). If FRMD4A 
is similarly involved in the regulation of ARF6 activation within the CNS, changes in its 
expression might cause perturbations in membrane trafficking and actin cytoskeleton 
dynamics. It is also noteworthy, that ARF6 has been suggested as a mediator of BACE1 
endocytosis (Sannerud et al. 2011), thus FRMD4A downregulation in the neurons might have 
an effect on BACE1 localization and consequently amyloidogenic processing of APP. 
Connection to Aβ production is supported by the finding that several FRMD4A 
polymorphisms correlate with plasma levels of Aβ40 and Aβ42 (Lambert et al. 2013a). 
Furthermore, recently a duplication of 13 nucleotides in FRMD4A that causes a non-
synonymous frameshift and a truncated protein product was identified as a cause of 
recessively inherited severe intellectual disability with structural brain abnormalities, 
emphasizing that FRMD4A is critical for the normal development and function of the CNS 
(Fine et al. 2014).  
2.4.3 Immune functions 
Dysregulation of the immune response and neuroinflammation are established processes in 
AD pathogenesis (Heneka et al. 2015, Takeda et al. 2014). GWA studies have identified loci 
within MS4A gene cluster, INPP5D, and HLA-DRB5 that are related to immune system 
operation. 
2.4.3.1 MS4A 
SNPs within the MS4A gene cluster have been identified to associate with AD occurence 
(Hollingworth et al. 2011). Amongst the AD-associated SNPs in this region are rs610932 in 3’ 
untranslated region (UTR) of MS4A6A, rs670139 in the intergenic region between MS4A4E 
(being closer to the SNP) and MS4A6A, listed among the top10 associations on AlzGene, as 
well as the rs983392 SNP, identified in the recent meta-analysis, upstream of MS4A6A. 
Although the functions of MS4A6A or MS4A4E are unknown, other members of the family 
have been implicated in calcium homeostasis and immune functions such as T cell activation 
(Howie et al. 2009, Ishibashi et al. 2001, Zuccolo et al. 2013), and the close homology shared 
by this gene family of 16 members suggest they also share similar functions (Liang et al. 
2001). Both disturbances of calcium homeostasis or alterations in immune response could 
affect AD pathogenesis (Engelhardt et al. 2012, LaFerla 2002). Increased MS4A6A expression 
has been linked to a more extensive tau- and Aβ-related neuropathology (Karch et al. 2012), 
as well as higher levels of MS4A6A protein in the plasma of AD patients as compared to 
control individuals or subjects with MCI (Proitsi et al. 2014). The protective minor allele of 
the rs610932 SNP is associated with lower expression levels of MS4A6A (Proitsi et al. 2014). 
Together these findings suggest that high expression levels of MS4A6A might be harmful, 
possibly due to increased cellular calcium levels or effects on immune response. It should be 
remembered, that although MS4A6A and MS4A4E are usually mentioned as the AD 
susceptibility genes in this locus, altogether 6 genes reside within the LD block marked by 
the associated SNPs (Hollingworth et al. 2011), and thus it is possible that some of these other 
genes (MS4A3, MS4A2, MS4A4A, MS4A6E), or a combination of these genes, are involved 
with AD. Finally, MS4A4A expression levels are associated with the genotype of more 
weakly AD-associated rs2304933 in the temporal cortex and cerebellum of AD and non-AD 
individuals, thus it has been suggested that this gene has a role in AD (Allen et al. 2012). 
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2.4.3.2 INPP5D 
INPP5D regulates cytokine signaling and plays a role in several inflammatory responses 
(Leung et al. 2009, Metzner et al. 2009). Increased levels of INPP5D in the blood of ischemic 
stroke patients have been linked to an increased risk of hemorrhagic transformation, which 
is associated with increased permeability of the BBB and might thus have some common 
mechanisms with AD (Jickling et al. 2013). Additionally, binding of INPP5D with AD-
associated CD2AP has been reported in plasmacytoid dendritic cells (Bao et al. 2012). 
2.4.3.3 HLA-DRB5 
HLA-DRB5 locus identified in the meta-analysis resides within the major histocompatibility 
complex II (MHCII) region involved in immune response (Trowsdale et al. 2013). 
Interestingly, this locus is also associated with PD and multiple sclerosis (International 
Multiple Sclerosis Genetics Consortium et al. 2011, International Parkinson Disease 
Genomics Consortium et al. 2011, Saiki et al. 2010). In a mouse model of PD, MHCII signaling 
activates microglia, whereas knockout of MHCII is protective against neurodegeneration 
induced by abnormal accumulation of α-synuclein protein (Harms et al. 2013), suggesting 
this locus might have similar effects in AD characterized by accumulation of Aβ and tau, and 
activation of microglia (Rosenthal et al. 2014). Furthermore, a recent study identified DNA 
methylation changes within HLA-DRB5 locus that associate with Aβ load and tau tangle 
density (Yu et al. 2015). 
2.4.4 Focal adhesions and integrin signaling 
Amongst the most recently identified AD-associated loci, FERMT2, CASS4, and PTK2B have 
described functions in the integrin signaling and/or focal adhesions. Integrins are 
transmembrane receptors formed of heterodimers of α- and β-subunits and they mediate the 
association between the extracellular matrix and the adhesion complex inside the cell (Geiger 
et al. 2001). Signaling cascades at focal adhesions initiated by interactions with the 
extracellular matrix have diverse roles in regulating the proliferation, differentiation, cell 
cycle, and cell death (Geiger et al. 2001). Aβ fibrils can interact with integrins, and subsequent 
disturbances in focal adhesion signaling cascades have been suggested as a mechanism by 
which neuronal cell cycle re-entry and neuronal cell death in AD could be induced 
(Caltagarone et al. 2007). 
2.4.4.1 FERMT2 
FERMT2 is ubiquitously expressed and encodes the protein fermitin family homolog 2, also 
known as kindlin-2. The three members of the kindlin protein family have crucial function 
in integrin regulation and signaling and formation of focal adhesions (Calderwood et al. 2013, 
Huet-Calderwood et al. 2014, Karakose et al. 2010, Larjava et al. 2008). Knock-down of 
FERMT2 in cell models leads to defects in β1 and β3 integrin activation, focal adhesion 
formation and cell spreading, whereas complete Fermt2 deficiency in mice leads to embryonic 
lethality (Dowling et al. 2008, Montanez et al. 2008, Pluskota et al. 2011, Shi et al. 2007). A 
recent study in Drosophila suggests that the function of FERMT2 in AD pathogenesis is 
related to modulation of tau pathology (Shulman et al. 2014a). 
2.4.4.2 CASS4 
CASS4 is a member of CAS (CRK-associated substrate) adaptor protein family with three 
other members: BCAR1, NEDD9 and EFS (Deneka et al. 2015). These proteins act as scaffolds 
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assembling larger signaling complexes. CASS4 is expressed at highest levels in lungs and 
spleen, but also in other tissues and organs, including the brain (Singh et al. 2008). Like other 
CAS family proteins, CASS4 mediates integrin-dependent attachment signaling at focal 
adhesions (Singh et al. 2008). Interestingly, a paralog of CASS4, NEDD9, interacts with the 
protein product of another AD risk gene PTK2B at focal adhesions, where PTK2B 
phosphorylates NEDD9. Sequence homology suggests that CASS4 might also be able to 
interact with PTK2B (Singh et al. 2008). NEDD9 has also been suggested to associate with AD 
risk, however this locus has not been among the genome-wide significant signals in GWASs 
(Li et al. 2008). The Drosophila ortholog of BCAR1, p130CAS, has been shown to bind CMS, 
the ortholog of AD-associated CD2AP (Kirsch et al. 1999). How CASS4 affects the AD 
pathogenesis is not known, however SNPs within CASS4 associate with AD and AD-related 
neuropathological features (Beecham et al. 2014, Lambert et al. 2013b).  
2.4.4.3 PTK2B 
PTK2B is a member of focal adhesion kinase (FAK) family (Lev et al. 1995). PTK2B is activated 
via autophosphorylation and phosphorylation by Src-family kinases in response to stimuli 
such as intracellular calcium levels (Avraham et al. 2000, Lev et al. 1995). PTK2B regulates 
neurite outgrowth in PC-12 and SH-SY5Y cells (Ivankovic-Dikic et al. 2000), and is involved 
in the long-term potentiation in the CA1 region in the hippocampus (Huang et al. 2001). A 
recent study showed that stress-induced phosphorylation of NUP62 by PTK2B might be 
involved in dendritic shrinkage in the hippocampus, in the context of chronic stress 
(Kinoshita et al. 2014). This mechanism might be linked to AD pathogenesis, as hippocampus 
is one of the earliest affected brain regions in AD. 
2.4.4.4 EPHA1 
EPHA1 belongs to ephrin (Eph) receptor family within the larger family of receptor tyrosine 
kinases. Eph receptors bind their membrane-anchored ligands, ephrins, on the adjacent cells, 
thus initiating bidirectional signaling between the two cells (Bruckner et al. 1997, Davy et al. 
1999, Holland et al. 1996).  Members of the ephrin receptor family have established roles in 
brain development, axon guidance and synapse formation and plasticity, but other roles such 
as cell adhesion have also been reported (Fox et al. 2004, Lai et al. 2009, Wilkinson 2001). 
However, the functions of EPHA1 are less well known. Inhibition of cell spreading and 
migration has been reported after activation of EPHA1, and EPHA1 was shown to interact 
with ILK, which has a role in integrin signaling (Yamazaki et al. 2009). Based on these reports, 
the role of EPHA1 in AD might be linked to the synaptic functions or integrin signaling. AD-
associated SNPs within EPHA1 have been reported to correlate with increased rate of 
memory decline (Carrasquillo et al. 2015) and nominally associate with dementia progression 
(Wang et al. 2015). EPHA1 SNPs have also been shown to correlate with neuroimaging 
measurements such as atrophy of hippocampus, occipitotemporal gyrus and inferior 
temporal gyrus, whereas no association with CSF biomarkers Aβ42, t-tau or p-tau was found 
(Wang et al. 2015).  
2.4.5 Transcription or splicing 
Loci related to alternative splicing (CELF1), transcription (MEF2C), and histone methylation 
(ZCWPW1) have been identified in AD GWASs. Alternative splicing is an important source 
of variation allowing different transcripts to be produced from a single gene. Over 90% of 
human genes that contain multiple exons undergo alternative splicing events (Pan et al. 
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2008), and disturbances in alternative splicing have been reported in many 
neurodegenerative diseases (Mills et al. 2012). Dysregulation of transcript levels as well as 
methylation have also been implicated in AD pathogenesis (Chen et al. 2013, Yu et al. 2015). 
2.4.5.1 CELF1 
The rs10838725 SNP within the CELF1 locus confers a risk effect for AD. The CELF protein 
family members are evolutionarily conserved RNA binding proteins with roles in alternative 
splicing, mRNA decay and translational regulation (Gallo et al. 2010). CELF1 was first 
identified in the context of myotonic dystrophy type 1 (DM1), a progressive heritable muscle 
wasting disease, where stabilization of CELF1 via increased phosphorylation leads to 
aberrant splicing of several transcripts. Interestingly, aged individuals suffering from DM1 
also develop neurodegeneration and neurofibrillary aggregates of tau (de Leon et al. 2008, 
Vermersch et al. 1996, Sergeant et al. 2001). Other members of the CELF family, including 
CELF2, 3 and 4 have been shown to affect the splicing of tau exons 2, 3, 6 and 10 in vitro 
(Chapple et al. 2007, Leroy et al. 2006, Wang et al. 2004), suggesting that CELF1 might be 
associated with tau pathway in AD. This hypothesis is supported by the finding that the 
Drosophila CELF1 homolog is a modulator of tau toxicity in that organism (Shulman et al. 
2014a). However, CELF1 also regulates a network of transcripts related to important cellular 
processes such as cell growth, development and apoptosis by mediating their decay 
(Vlasova-St Louis et al. 2011), therefore the risk effect of CELF1 in AD might be mediated by 
adverse effects on these processes. 
2.4.5.2 MEF2C 
MEF2C is a transcription factor which within the CNS facilitates hippocampus-dependent 
learning and memory by regulating excitatory synapse formation during refinement of 
synaptic connectivity (Barbosa et al. 2008). Furthermore, the Drosophila ortholog, Mef2, has 
been shown to mediate circadian clock information by transcriptionally activating the 
neuronal remodeling machinery (Sivachenko et al. 2013).  Mutations in MEF2C have been 
linked to severe mental retardation syndrome including seizures and stereotypic movements 
(Bienvenu et al. 2013, Le Meur et al. 2010). Recently, MEF2C polymorphisms were found to 
associate with general cognitive function in middle-aged and older individuals (Davies et al. 
2015), and to nominally associate with dementia progression (Wang et al. 2015).  
2.4.5.3 ZCWPW1 
ZCWPW1 is one of the least studied AD risk genes. It contains zf-CW domain, which in other 
proteins has been described to have chromatin-related functions including control of the 
methylation state of the histone H3, which determines whether the chromatin is in 
transcriptionally active or repressed state (He et al. 2010, Perry et al. 2003). The AD-associated 
SNP is in intronic sequence of ZCWPW1, and its function is unknown. However, the LD 
region around the SNP contains nine additional genes, and it is possible that some of these 
other genes are functionally relevant (Lambert et al. 2013b). AD-specific changes in 
expression of two genes in this locus, C7ORF61 and TSC22D4, have been reported 
(Humphries et al. 2015). 
2.4.6 Genes with unclear functions in AD 
Three AD-associated loci, SLC24A4, NME8, and DSG2 do not easily fit into any of the 
functional groups presented above. However, results from biomarker association analysis 
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support the role of SLC24A4 and NME8 in AD pathogenesis, whereas the role of DSG2 
remains unclear. 
2.4.6.1 SLC24A4 
SLC24A4 is a member of a family of genes that encode potassium-dependent sodium-calcium 
exchangers. The SLC24A4 protein has been linked previously to iris development, and skin 
and hair color variation (Han et al. 2008, Sulem et al. 2007), hardening of dental enamel 
(Herzog et al. 2015, Parry et al. 2013), and the risk of hypertension (Adeyemo et al. 2009). The 
function of SLC24A4 within the brain is unknown, however, it is known to be expressed there 
(Li et al. 2002). A recent study in a community-based cohort revealed that the methylation 
status of CpG dinucleotides within SLC24A4 is associated with Aβ load and pathological 
diagnosis of AD (Yu et al. 2015). These findings support the suggested role of SLC24A4 in 
AD pathogenesis. 
2.4.6.2 NME8 
NME8 is associated with primary ciliary dyskinesia, bone mineral density, knee 
osteoarthritis risk, and susceptibility to oxidative stress in sperm (Duriez et al. 2007, Shi et al. 
2008, Smith et al. 2013, Yerges-Armstrong et al. 2014). Modification of antioxidant action and 
thus regulation of oxidative stress levels is hypothesized as a potential mechanism related to 
AD pathogenesis (Rosenthal et al. 2014). The genotype of NME8 related SNP, rs2718058, was 
found to associate with CSF t-tau levels and neuroimaging traits such as hippocampal and 
occipital atrophy (Liu et al. 2014). Thus far studies have reported expression only in testis 
and respiratory epithelial cells (Escudier et al. 2009, Smith et al. 2013), thus it is unclear 
whether NME8 is expressed within the brain and how it is involved with AD pathogenesis. 
It has been suggested, that the rs2718058 SNP polymorphism acts as an expression 
quantitative trait locus (eQTL) regulating the expression of some other gene (Rosenthal et al. 
2014). 
2.4.6.3 DSG2 
The DSG2 SNP, rs8093731, was identified in a meta-analysis to associate positively with AD 
risk. However, the signal was based on a single SNP and was not supported by surrounding 
SNPs in LD, and the association was not replicated in the stage 2 validation analysis (Lambert 
et al. 2013b). Therefore, it is possible that this locus does not actually associate with AD risk. 
DSG2 encodes for desmoglein 2, which among the other desmoglein proteins is a 
desmosomal cadherin and essential component of the desmosome (Schwarz et al. 1990). 
Mutations in DSG2, amongst other desmosome-related genes, have an established role in the 
arrhythmogenic right ventricular cardiomyopathy (Awad et al. 2006, Pilichou et al. 2006, van 
der Zwaag et al. 2009).  
2.4.7 DHCR24 
DHCR24 (3-β-hydroxysteroid-Δ-24-reductase), also known as seladin-1 (selective 
Alzheimer’s disease indicator-1) was first identified based on lower transcript levels in the  
affected than unaffected brain regions of AD patients, and it was suggested to underlie the 
selective vulnerability of these regions to neurodegeneration (Greeve et al. 2000, Iivonen et 
al. 2002). Later, mutations in the DHCR24 gene were found to cause desmosterolosis, a rare 
autosomal recessive disorder in which a deficit in the cholesterol biosynthesis leads to 
elevated levels of cholesterol precursor desmosterol, thus DHCR24 was established as the 
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enzyme responsible for conversion of desmosterol to cholesterol (Waterham et al. 2001). 
Lately, the down-regulation of DHCR24 in AD was questioned, as it has not been replicated 
in more recent studies, and the use of the official name DHCR24 instead of seladin-1 was 
encouraged (Sharpe et al. 2012). However, investigations of genetic polymorphisms in the 
DHCR24 have suggested increased susceptibility to AD among male carriers of T allele in 
rs600491 in two independent cohorts (Feher et al. 2012, Lamsa et al. 2007). Thus, although not 
confirmed in large-scale GWAS studies, these findings suggest that DHCR24 might be 
involved with AD in a subset of patients. Furthermore, and perhaps more importantly, 
functional studies have revealed that DHCR24 possesses neuroprotective properties, thus 
maintaining interest on this protein. 
DHCR24 has been extensively studied in the context of different stress conditions linked 
to neurodegenerative diseases, including oxidative stress, endoplasmic reticulum (ER) stress, 
Aβ-induced neurotoxicity and apoptosis, and the evidence strongly suggests that DHCR24 
has an important role in neuroprotection (Cecchi et al. 2008, Crameri et al. 2006, Greeve et al. 
2000, Kuehnle et al. 2008, Lu et al. 2014, Sarajarvi et al. 2009, Wu et al. 2004). In addition to 
the cholesterol activity in the C-terminal region, DHCR24 was described to have an 
oxidoreductase domain near its N-terminus and act as an H2O2-scavenger (Lu et al. 2008, 
Waterham et al. 2001). Some studies have linked the neuroprotective effect of DHCR24 
directly to the cholesterol activity, showing cholesterol-dependent protection from oxidative 
stress or Aβ and maintenance of lipid raft integrity (Crameri et al. 2006, Kuehnle et al. 2008). 
Other studies have not identified whether the neuroprotection is mediated by the cholesterol 
activity, the H2O2-scavenging activity or both (Greeve et al. 2000, Wu et al. 2004). 
 Furthermore, it has been shown that decreased levels of DHCR24 lead to stabilization of 
BACE1 and consequently to increased β-amyloidogenic processing of APP in apoptotic 
conditions in vitro (Sarajarvi et al. 2009). Based on these findings, it has been suggested that 
augmentation of DHCR24 levels in the areas vulnerable to or undergoing neurodegeneration 
might provide a therapeutic mean to intervene with AD onset and progression, even though 
this gene might not be involved in the induction of AD pathogenesis.  
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3 Aims of the Study 
AD is a devastating neurodegenerative disorder with currently only symptomatic treatment 
available. The exact molecular mechanisms behind AD remain unclear. The aim of this thesis 
was to shed light on the molecular mechanisms of AD and open up the road for new options 
for therapeutic treatment by 1) investigating how the genetic risk factors associate with AD-
related pathogenic changes in human samples, and 2) by studying and reviewing the 
potential of DHCR24 and LRP1 to intervene with AD-related pathological processes. 
The specific aims were as follows: 
I To investigate the associations between GWAS-identified AD risk loci and measures 
of AD pathogenesis in the brain and CSF individually and in combination using a 
polygenic risk score. 
II To assess the transcription and splicing of AD risk genes in the temporal cortex in 
relation to AD-related neurofibrillary pathology and to elucidate the effects of risk 
genes on AD-related amyloid and tau pathways in vitro. 
III To characterize the potential of DHCR24 to protect neuronal cells against AD-related 
cellular stress conditions ER stress, apoptosis, and neuroinflammation in vitro. 
IV To review the role of LRP1 in AD-related pathways, especially Aβ clearance from the 
CNS, and to evaluate the potential of LRP1 as a therapeutic target in AD. 
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4 Materials and methods 
The methods used in this thesis are summarized in Table 2. More information on the subjects, 
materials and methods are provided in Tables 3–10. Detailed descriptions of the study 
materials and experimental procedures are provided in the original articles I-III. 
 
Table 2. Summary of the methods used in this thesis 
Method Description Original 
article 
More 
information 
Genetics methods SNP genotyping 
Genetic associations with AD risk 
Polygenic risk score 
Genetic associations with CSF biomarkers 
and endophenotypes 
I, II 
I 
I 
I, II 
Table 4 
Table 4 
Table 4 
Table 4 
Methods to study gene 
expression 
RNA isolation 
Agilent Exon array 
Quantitative real-time polymerase chain 
reaction (qPCR) 
II, III 
II 
II, III 
 
Table 4 
Table 7 
Methods to study 
proteins 
Western blotting 
ELISA-based methods 
Enzyme activity assays 
II, III 
I, II, III 
I, II 
Table 6 
Table 9 
Table 9 
Cell culture Secondary cell line culture 
Mouse primary cortical neuron culture 
II, III 
III 
Tables 8, 10 
Tables 8, 10 
Cell biology methods Transient transfection of cDNA 
Lentivirus-mediated gene transfer 
siRNA-mediated gene silencing 
II, III 
III 
II 
Table 5 
Table 5 
Abbreviations: SNP, single nucleotide polymorphism; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; 
ELISA, enzyme-linked immunosorbent assay; cDNA, complementary DNA; siRNA, short interfering RNA. 
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Table 3. Demographic details of the clinical (study I) and neuropathological (studies I and II) 
cohorts 
Abbreviations: AD, Alzheimer’s disease; n, sample size; SD, standard deviation; MMSE, Mini-Mental State 
Examination. 
a Clinical cohort AD cases: age at onset; controls: age at examination; neuropathological cohort: age at 
death. 
b Available for 7 individuals. 
c Available for 5 individuals. 
d Available for 10 individuals. 
  
 Clinical cohort Neuropathological cohort 
 AD n=890 
Control 
n=701 
Braak 0-II  
n=27  
(Study II: n=28) 
Braak III-IV 
n=13 
Braak V-VI 
n=19 
Clinical dementia status 
control/demented 0/890 701/0 16/11 2/11 0/19 
Agea mean (y) ± SD 69.8 ± 8.2 69.1 ± 6.2 
79.1 ± 11.1  
(79.2 ± 10.9) 
78.7 ± 6.8 81.3 ± 7.0 
Gender, males/females 294/596 281/420 13/14 (14/14) 2/11 2/17 
MMSE score, mean ± 
SD 19 ± 5 - 22 ± 8
b 16 ±4c 15 ± 7.0d 
APOE ε2/ε3/ε4 allelic 
distribution, % 2/53/45 4/80/16 0/80/20 4/58/38 0/45/55 
Brain weight, mean (g), 
± SD - - 
1250.7 ± 186.0 
(1249.5 ± 182.6) 
1103.7 ± 
156.0 
1040.3 ± 
182.9 
Post mortem delay, 
mean (h) ± SD - - 
18.2 ± 19.9  
(18.0 ± 19.6) 
15.8 ± 16.1 7.1 ± 5.0 
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Table 4. AD-associated genes and polymorphisms studied in the clinical (study I) and 
neuropathological (studies I and II) cohorts 
Chromosome, 
gene 
Polymorphism Alleles 
(major/ 
minor) 
Studied for 
associations 
with AD and 
CSF 
biomarkers 
Included 
in the 
polygenic 
risk score 
Included in 
the exon 
array 
Original 
article 
1, CR1 rs3818361 C/T - + + I, II 
2, BIN1 rs744373 A/G - + + I, II 
1, PSEN2 - - - - + II 
2, INPP5D rs35349669 C/T + + - I 
5, MEF2C rs190982 A/G + + - I 
6, CD2AP rs9349407 G/C - + + I, II 
6, HLA-DRB5 rs9271192 A/C + + - I 
7, NME8 rs2718058 A/G + + - I 
7, EPHA1 rs11771145 G/A + + - I 
8, CLU rs11136000 C/T - + + I, II 
8, PTK2B rs28834970 T/C + + - I 
10, FRMD4A rs7081208 
rs2446581  
rs17314229  
G/A  
G/A 
C/T 
- - + I, II 
11, BACE1 - - - - + II 
11, CELF1 rs10838725 T/C + + - I 
11, MS4A4E rs670139 G/T - + + I, II 
11, MS4A6A rs610932 G/T - + + I, II 
11, PICALM rs3851179 G/A - + + I, II 
11, SORL1 rs11218343 T/C + + - I 
14, FERMT2 rs17125944 T/C + + - I 
14, PSEN1 - - - - + II 
14, SLC24A4 rs10498633 G/T + + - I 
17, MAPT - - - - + II 
18, DSG2 rs8093731 C/T + + - I 
19, ABCA7 rs3764650 T/G - + + I, II 
19, APOE ε2, ε3, ε4 ε2, ε3, ε4 + + + I 
19, CD33 rs3865444 C/A - + + I, II 
20, CASS4 rs7274581 T/C + + - I 
21, APP - - - - + II 
 
Table 5. Plasmid constructs used in this thesis. 
Construct Description Origin Original 
article 
pCMV6-AC-DHCR24 Includes human DHCR24 cDNA OriGene III 
pcDNA3.1 Empty vector, used as a control Invitrogen III 
pLenti-CMV-h-DHCR24 Includes human DHCR24 cDNA Applied Biological Materials III 
pLenti-III-HA Empty vector, used as a control Applied Biological Materials III 
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Table 6. Primary antibodies used in this thesis 
Antibody Target Source 
and 
clonality 
Application Manufacturer Original 
article 
β-actin Total β-actin Mouse mAb WB Abcam III 
AKT Total RAC-alpha serine/threonine-protein kinase Rabbit pAb WB 
Cell Signaling 
Technology III 
p-AKT  AKT phosphorylated at Ser473 Rabbit pAb WB Cell Signaling Technology III 
APP/A8717 Amyloid precursor protein C-terminal Rabbit pAb  WB Sigma III 
APP/6E10 Soluble Amyloid precursor protein Mouse mAb WB BioSite III 
BACE1 
/D10E5 
Total β-site APP cleaving 
enzyme Rabbit mAb WB 
Cell Signaling 
Technology III 
Caspase-3 Total caspase-3 Rabbit pAb WB Cell Signaling Technology III 
CHOP Total C/EBP homologous protein Mouse mAb WB 
Affinity 
BioReagents III 
DHCR24 
(C59D8) 
Total 3β-hydroxysteroid Δ24 
reductase Rabbit mAb WB 
Cell Signaling 
Technology III 
ERK 2 Total Extracellular-signal related kinase 1 and 2  Rabbit pAb WB 
Santa Cruz 
Biotechnology III 
p-ERK  
Extracellular-signal related 
kinase 1 and 2  phosphorylated 
at Tyr204 
Mouse mAb WB Santa Cruz Biotechnology III 
GAPDH Total Glyceraldehyde-3-phosphatase dehydrogenase Mouse mAb WB Abcam III 
GAPDH Total Glyceraldehyde-3-phosphatase dehydrogenase Mouse mAb WB Millipore II 
MAP-2 Total Microtubule-associated protein 2 Mouse mAb IHC Sigma III 
tau-5  Total tau Mouse mAb WB Invitrogen II 
tau/AT8  Tau phosphorylated at Ser202 and Thr205 Mouse mAb WB Thermo Scientific II 
tau/AT100  Tau phosphorylated at Thr212 and Ser214 Mouse mAb WB Thermo Scientific II 
tau/PHF-6 Tau phosphorylated at Thr231 Mouse mAb WB Millipore II 
tau/PHF13  Tau phosphorylated at Ser396 Mouse mAb WB Cell Signaling Technology II 
Abbreviations: Ser, serine; Tyr, tyrosine; Thr, threonine; mAB, monoclonal antibody; pAb, polyclonal 
antibody; WB, Western blot; IHC, immunohistochemistry. 
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Table 7. Primers used for quantitative PCR in this thesis 
Gene Forward primer (5’–3’) Reverse primer (5’–3’) Original article 
ABCA1 GAGGAATGCCCACGCAAATC AGGCCCAGACCTGTAAATGC III 
ABCA7 AGCCCGCAACATCTCAAG CTCACGGAAAAGTCCTCCAC II 
APOE GGTCGCTTTTGGGATTACCT TTCCTCCAGTTCCGATTTGT II 
BIN1 TTCCTCCAGTTCCGATTTGT GATCACCAGCACCACATCAC II 
CD2AP GGTGGCTGGAAGGAGAACTA GTGGATGTGGCTGAATTCCT II 
CD33 GACCAGAGCAGGAGTGGTTC GTGGTAGGGTGGGTGTCATT II 
CLU CCAGTGGAAGATGCTCAACA AGCTTCACGACCACCTCAG II 
CR1 GCCAGGCCTACCAACCTAAC GCCATTCACAGGATCTGGAG II 
DHCR24 CAAGCCGTGGTTCTTTAAGC CATCCAGCCAAAGAGGTAGC III 
FRMD4A ATCAAGCCCAAAATGTGGAG CTGCAAGGAGTTGCTTCCTC II 
GAPDH GATCATTCAGCTCAGCAAACA GTATTCAAACCCAAGCTACTCAGA III 
MS4A4E AACCATGCAAGGAATGGAAC TTCCCATGCTAAGGCTCATC II 
MS4A6A CTCCTGATACAGGGCCAAAG ACTGCAGTGAGGCAGGATTT II 
PICALM ACCCCCTGTAATGGCCTATC CTCCTGATACAGGGCCAAAG II 
SREBF1 GGGAGGGCTTCCTGTAGAGA TCTTGAAGCCTTCCTGAGCG III 
TREM2 TGGCACTCTCACCATTACGC GAGGCTCCTGGAGATGCTGTG II 
 
Table 8. Cell lines and primary cells used in this thesis 
Cells Description Culture conditions Original 
article 
BV2 Mouse microglial 
secondary cell line 
RPMI medium, 10% FBS, 2 mM L-
glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin. In coculture 
with mouse primary cortical neurons, 
see below 
III 
HEK293-T Human embryonic 
kidney secondary cell 
line 
DMEM, 10% FBS, 1% L-glutamine, 
1% penicillin/streptomycin 
II 
Mouse primary cortical 
neurons 
Primary cortical neurons 
prepared from 
JAXC57BL/6J mouse 
brains on embryonic 
day 18 
Neurobasal medium, 2% B27, 2 mM 
L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin 
III 
SH-SY5Y-APP751 Human neuroblastoma 
secondary cell line 
stably overexpressing 
human APP751 isoform 
DMEM, 10% FBS, 2mM L-glutamine, 
100U/ml penicillin, 100 µg/ml 
streptomycin, 200 µg/ml geneticin 
III 
Abbreviations: FBS, fetal bovine serum; DMEM, Dulbecco’s modified Eagle’s medium. 
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Table 9. Biochemical assays used in this thesis 
Measured target  Assay kit Supplier Sample type 
analyzed 
Original 
article 
Aβ40 levels Human/Rat β 
amyloid 40 ELISA 
kit 
Wako, Osaka, Japan Conditioned media III 
Aβ42 levels Innotest β-
amyloid(1-42) 
ELISA 
Innogenetics, Ghent, 
Belgium 
Human CSF I, II 
Human/Rat β 
amyloid 42 (High 
sensitive)ELISA kit 
Wako, Osaka, Japan Soluble fraction of 
human brain tissue  
I, II 
 
Conditioned media III 
α-secretase 
activity 
α-secretase assay 
kit K366-100 
BioVision, CA, USA Membrane fraction of 
human brain tissue 
I, II 
β-secretase 
activity 
β-secretase assay 
kit K360-100 
BioVision, CA, USA Membrane fraction of 
human brain tissue 
I, II 
Cell viability Cell counting kit 8 
(cck-8) 
Dojindo Molecular 
Technologies, Maryland, 
USA 
SH-SY5Y-APP751 cell 
cultures 
III 
Neuronal viability MAP-2 IHC 
detected by ABTS 
peroxidase 
substrate kit 
Vector Biolabs Mouse primary 
cortical neuron 
cultures 
III 
γ-secretase 
activity 
Fluorogenic γ-
secretase 
substrate 
Calbiochem Membrane fraction of 
human brain tissue 
I, II 
Nitric oxide levels Griess Reagent Kit 
for Nitrite 
Determination 
Life Technologies Conditioned media III 
Phosphorylated tau 
levels 
Innotest Phospho-
tau(181P) ELISA 
Innogenetics, Ghent, 
Belgium 
Human CSF I, II 
Total cholesterol 
levels 
Fluorometric Total 
Cholesterol Assay 
Kit 
Cell Biolabs SH-SY5Y-APP751 cell 
lipid fraction 
III 
Total protein levels BCA protein assay 
kit 
Thermo Scientific Cell culture lysates III 
Total tau levels Innotest hTau Ag 
ELISA 
Innogenetics, Ghent, 
Belgium 
Human CSF I, II 
TNF-α levels Mouse TNF alpha 
ELISA Ready-SET-
Go! 
Affymetrix, San Diego, 
CA, USA 
Conditioned media III 
Abbreviations: CSF, cerebrospinal fluid; IHC, immunohistochemistry 
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Table 10. Compounds used in treatments of cell cultures in the original article III 
Compound Description Concentration and 
treatment time 
Manufacturer 
1400W dihydrochloride Selective iNOS inhibitor 20µM, 1h pre-
treatment before LPS+ 
IFN-γ  
Tocris 
9-cis-retinoic acid (9-cis-RA) Retinoic X receptor agonist 10µM, 24h  
Cycloheximide (CHX) Inhibitor of de novo protein synthesis 30µg/ml; 0, 20, 40, 
80min 
Sigma 
Interleukin-10 (IL-10), murine 
recombinant 
Anti-inflammatory cytokine 50ng/ml, 1h pre-
treatment before LPS+ 
IFN-γ  
Peprotech 
Interferon-γ (IFN-γ), mouse 
recombinant 
Pro-inflammatory cytokine, used 
together with LPS to induce 
neuroinflammation 
20ng/ml, 48h Sigma 
Lipopolysaccharide (LPS), 
E.coli serotype 026:B6 
Major component of the outer 
membrane of Gram-negative bacteria, 
used together with IFN-γ to induce 
neuroinflammation 
200ng/ml, 48h Sigma 
Paxilline Liver X receptor agonist 10µM, 24h  
Staurosporine (STS) Inducer of apoptosis 1µM, 6h Sigma 
T0901317 Liver X receptor agonist 1µM, 24h  
Tunicamycin (TM) Inhibitor of N-linked glycosylation, 
induces ER stress 
5µg/ml, 6h Sigma 
Abbreviations: iNOS, inducible nitric oxide synthase; ER, endoplasmic reticulum. 
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5 Results 
5.1 AD RISK LOCI ASSOCIATE WITH MEASURES OF AD PATHOGENESIS 
5.1.1 Variants in SLC24A4, EPHA1 and FERMT2 loci nominally associate with AD risk and 
CSF biomarkers in a Finnish clinical AD cohort (I) 
Large-scale genome-wide association studies comparing AD patients and healthy controls 
have identified over 20 loci affecting the risk of AD. Twelve of them (within or near the genes 
HLA-DRB5, PTK2B, SORL1, SLC24A4, DSG2, INPP5D, MEF2C, NME8, CELF1, FERMT2, 
CASS4 and EPHA1, see Table 4) which had not been previously assessed in Finnish cohorts 
were selected for this study and analyzed for association with AD risk in a clinical cohort of 
890 AD patients and 701 controls. Association with CSF biomarkers was studied in a 
subgroup of 220 AD cases. APOE, the strongest known genetic risk factor for AD was 
included for comparative purposes. An additive model, adjusted for age and gender, was 
used to calculate the associations. APOE ε4 carriers in the clinical cohort had a significantly 
higher risk of AD than non-carriers (P<0.001). Furthermore, a nominally significant 
protective effect was detected among the minor allele carriers in the rs10498633 and 
rs11771145 SNPs, located in the SLC24A4 and EPHA1 loci, respectively. These results are in 
line with the findings reported in the recent meta-analysis (Lambert et al. 2013b). The 
remaining loci did not associate with AD risk.  
Among the subgroup of 220 AD patients with CSF samples, APOE ε4 carriers had 
significantly lower CSF Aβ42 levels (false discovery rate (FDR) corrected P=0.01) and 
nominally increased CSF t-tau levels (uncorrected P=0.006, FDR corrected P=0.07) as 
compared to non-carriers (Figure 8A). Interestingly, nominally increased CSF Aβ42 levels 
were detected among the minor allele carriers of the rs10498633 SNP in SLC24A4 locus 
(uncorrected P=0.05, FDR corrected P=0.2, Figure 8B) and the rs11771145 in EPHA1 locus 
(uncorrected P=0.03, FDR corrected P=0.18, Figure 8C), the two loci found to nominally 
associate with decreased AD risk in this cohort. Minor allele carriers of FERMT2 rs17125944 
were found to have nominally decreased CSF t-tau (uncorrected P=0.04, FDR corrected 
P=0.24, Figure 8D) and CSF p-tau (uncorrected P=0.02, FDR corrected P=0.24) levels. No 
associations were detected between the CSF biomarkers and the remaining loci. 
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Figure 8. The effect of AD-risk loci on CSF biomarker levels. A) Significantly decreased levels of 
CSF Aβ42 and a trend towards increased t-tau levels are detected among the carriers of one or 
two APOE ε4 alleles (n=71/120/63 for Aβ42, n=56/88/45 for t-tau). B) A trend toward increased 
CSF Aβ42 levels among the carriers of a minor T allele in SLC24A4 rs10498633 locus 
(n=182/62/7). C) A trend toward increased CSF Aβ42 levels among the carriers of a minor A 
allele in EPHA1 rs1771145 locus (n=106/110/35). D) Trend toward decreased t-tau and p-tau 
levels among the carriers of minor C allele in FERMT2 rs17125944 locus (n=144/40/4 for t-tau, 
n=139/38/3 for p-tau). 
5.1.2 Expression of AD risk genes MS4A6A, FRMD4A, CLU, and TREM2 changes in 
relation to AD-related neurofibrillary pathology (II) 
One approach to elucidate the functions of the genes in the GWAS loci is to study their 
expression in the affected tissue. In study II, the expression and splicing of 12 AD-associated 
risk genes (APOE, BIN1, CLU, ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, CD2AP, 
FRMD4A, and TREM2) and 5 genes encoding proteins involved in AD pathogenesis (MAPT, 
APP, PSEN1, PSEN2, and BACE1) was assessed in temporal cortex tissue samples in a 
neuropathological cohort of 60 individuals. The cohort was divided into three subgroups 
according to neurofibrillary pathology based on Braak staging: Braak 0-II (n=28), Braak III-
IV (n=13) and Braak V-VI (n=19) (Braak et al. 2006).  
First, a biochemical characterization of the temporal cortex tissue samples was carried out 
by measuring soluble Aβ42 levels as well as the activities of the α-, β- and γ-secretases. Higher 
concentrations of soluble Aβ42 were detected among the Braak V-VI group as compared to 
the Braak 0-II group (P=0.0003), along with higher β-secretase activity in both Braak III-IV 
and V-VI groups as compared to the Braak 0-II group. No differences in α- and γ-secretase 
activities were detected between the groups.  
The expression levels of the selected genes were then analyzed according to the degree of 
AD-related neurofibrillary pathology and the genotype of the SNP identified in GWAS 
(Table 4). Expression of MS4A6A and FRMD4A were found to linearly increase and decrease, 
respectively, in relation to increasing AD-related neurofibrillary pathology (Figure 9A-B). 
Analysis of individual exon expression levels in these genes revealed significantly increased 
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expression of exons 3 and 4 in both CLU and TREM2, in relation to increasing level of AD-
related neurofibrillary pathology (Figure 9C-D). Furthermore, nominally significant increase 
in the expression was observed in three other exons of CLU and in the 3’ UTR of TREM2, 
respectively. No statistically significant associations between the SNP genotypes and gene 
expression were detected, however BIN1 expression nominally associated with the rs744373 
SNP genotype. 
 
 
Figure 9. MS4A6A, FRMD4A, CLU and TREM2 are differentially expressed according to AD-related 
neurofibrillary pathology. A) MS4A6A expression is significantly increased according to increasing 
neurofibrillary pathology. B) FRMD4A expression is significantly decreased in relation to increasing 
neurofibrillary pathology. C) The expression of CLU exons 3 and 4 is significantly increased 
according to increasing neurofibrillary pathology. D) TREM2 exons 3 and 4 are differentially 
expressed according to increasing neurofibrillary pathology. Each dot in A-B represents one 
individual, in C-D the mean of all individuals in the group. 
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The expression and splicing of genes involved in the pathogenic pathways in AD, APP, 
PSEN1, PSEN2, BACE1, and MAPT did not change according to the AD-related 
neurofibrillary pathology. Correlating the expression levels of these genes with the 
biochemical measures revealed a negative correlation between β-secretase activity with both 
MAPT and PSEN2 gene expression. 
5.1.3 FRMD4A and ABCA7 associate with Aβ and tau pathways in vitro (II) 
The potential functional associations of the AD risk genes in Aβ production and tau 
phosphorylation pathways was studied using HEK293T cells expressing protein-fragment 
complementation assay (PCA) reporter systems for BACE1-APP, Pin1-tau, and GSK3β-tau 
interactions, combined with RNA interference- (RNAi)-mediated silencing of the target 
genes (Merezhko et al. 2014, Nykanen et al. 2012). The interaction between BACE1 and APP 
was significantly increased when CLU, ABCA7, CD2AP or FRMD4A were silenced, resulting 
in increased Aβ40 production in ABCA7- and FRMD4A- silenced cells. Silencing of APOE 
significantly increased Aβ40 production, even though the interaction between BACE1 and 
APP was unaffected. Interaction of tau with a regulator of its dephosphorylation, Pin1, was 
increased after silencing of ABCA7 and FRMD4A, coinciding with decreased levels of 
phospho-Ser202/Thr205 and increased levels of phospho-Ser396 tau in FRMD4A-silenced 
cells. Decreased levels of phospho-Ser202/Thr205 tau were detected also after silencing of 
CD33 and CD2AP, which had no effect on the Pin1-tau interaction. GSK3β is one of the key 
kinases involved in phosphorylation of tau, and its increased interaction with tau led to 
increased levels of phospho-Thr212/Ser214 and phospho-Thr231 tau in CD2AP- and 
FRMD4A-silenced cells, respectively. Increased interaction between GSK3β and tau after 
ABCA7 silencing did not lead to significant changes in the tau phospho-epitope levels, 
whereas phospho-Thr231 tau levels were increased in PICALM-silenced cells with no 
changes in the interaction between GSK3β and tau. 
5.1.4 Polygenic risk score of AD associates with Aβ levels and γ-secretase activity (I) 
As individual loci often have only small effects on AD risk, the joint effects of 22 AD-
associated loci were studied utilizing a polygenic risk score approach, as has been shown 
previously for e.g. schizophrenia (International Schizophrenia Consortium et al. 2009). The 
polygenic risk score was calculated separately for each individual in the cohort, and is based 
on the log-transformed locus-specific odds ratio (OR) reported in the meta-analyses (Table 1) 
(Bertram et al. 2007, Lambert et al. 2013b), weighted by the number of minor (risk or 
protective) alleles the individual carries in the locus. As the OR of APOE is considerably 
higher than that of any other locus, non-APOE polygenic risk score was calculated to evaluate 
separately the effects of APOE and the other loci. 
The polygenic risk score was first studied in a neuropathological cohort of 59 individuals, 
divided into three subgroups: Braak 0-II (n=27), Braak III-IV (n=13) and Braak V-VI (n=19) 
(Braak et al. 2006). Although there was a linear increase in the mean values of the polygenic 
risk score according to increasing Braak stages (Figure 10), this effect is mainly driven by the 
APOE locus. The mean of the polygenic risk score consisting of all 22 loci is higher than the 
APOE score only in the Braak V-VI group, and this increase is not statistically significant 
(Mann-Whitney U-test P=0.85). 
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Figure 10. Mean polygenic risk score, non-APOE polygenic risk score, and APOE risk score values 
within the neuropathological cohort. 
Soluble Aβ42 levels and the activity of α-, β-, and γ-secretases were measured from the 
temporal cortex tissue samples of the individuals of the neuropathological cohort. Analysis 
of these biochemical measurements revealed a significant positive correlation between 
soluble Aβ42 levels and both the polygenic risk score (r=0.439, P<0.001, Figure 11A) and non-
APOE polygenic risk score (r=0.289, P=0.03, Figure 11B). α- and β-secretase activities were not 
associated with the polygenic risk scores. However, γ-secretase activity positively correlated 
with non-APOE polygenic risk score (r=0.283, P=0.04, Figure 11D), but not with the polygenic 
risk score that included APOE (r=0.245 P=0.07, Figure 11C). 
 
 
 
Figure 11. Correlations between the polygenic risk scores and biochemical measurements on the 
temporal cortex of the neuropathological cohort. A-B) The polygenic risk score (A) and non-APOE 
polygenic risk score (B) significantly correlate with soluble Aβ42 levels. C-D) The non-APOE 
polygenic risk score (D) but not the polygenic risk score (C) significantly associates with γ-
secretase activity on the temporal cortex. N=59.  
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In a subset of the clinical cohort, with CSF samples available, both the APOE risk score 
and non-APOE polygenic risk score were significant determinants of CSF Aβ42 levels (Figure 
12). Linear regression model including APOE risk score, age and gender explained 10.8% of 
the variation among CSF Aβ42 levels, whereas adding non-APOE risk score in the model 
increased the amount of variance explained by 1.8%, for a total of 12.6%. APOE risk score 
also significantly associated with CSF t-tau, but only nominally with p-tau levels. Non-APOE 
risk score did not associate with CSF t-tau or p-tau. 
Figure 12. The amount of variance in CSF biomarker levels explained by the risk score based only 
on APOE genotype (gray), and the polygenic risk score based on 22 AD-associated loci excluding 
APOE (non-APOE risk score, black). Only a minor portion of the variance is explained by the other 
risk loci as compared to APOE. 
5.2 DHCR24 PROTECTS NEURONAL CELLS UPON LPS/IFN-γ-INDUCED 
NEUROINFLAMMATION 
DHCR24 is a protein shown to possess neuroprotective properties in different stress 
conditions related to neurodegenerative diseases, such as oxidative stress, ER stress and 
apoptosis. In study III, the neuroprotective mechanisms of DHCR24 were assessed utilizing 
transient DHCR24 overexpression during induced ER stress and apoptosis in human 
neuroblastoma SH-SY5Y secondary cell line stably overexpressing human APP751 isoform 
(SH-SY5Y-APP751), and upon neuroinflammation in a coculture of mouse primary cortical 
neurons and BV2 microglial cell line.  
5.2.1 DHCR24 overexpression increases APP levels but has no effect on cholesterol levels 
under normal conditions in SH-SY5Y-APP751 cells (III) 
Under normal growth conditions, DHCR24 overexpression led to increased levels of APP in 
SH-SY5Y-APP751 cells, coinciding with reduced APP-normalized Aβ40 levels in the 
conditioned media. Blocking de novo protein synthesis by cycloheximide treatment was used 
to reveal whether the increase in APP levels is due to stabilization of APP in the DHCR24-
overexpressing cells. However, no difference in the APP half-life was detected between the 
DHCR24-overexpressing and control cells, suggesting that APP degradation is not affected 
by DHCR24 overexpression. As DHCR24 has a role in cholesterol synthesis, the total 
41 
 
 
cholesterol levels were determined in DHCR24 overexpressing and control cells under 
normal conditions, but no differences were detected.  
5.2.2 DHCR24 overexpression cannot be induced by LXR/RXR agonists, and does not 
alleviate ER stress or apoptosis in SH-SY5Y-APP751 cells (III) 
It has been suggested, that increasing DHCR24 levels might have therapeutic potential in 
neurodegenerative diseases, and a study identifying DHCR24 as a liver X receptor α (LXR α) 
target gene led to the hypothesis, that LXR agonists could be used to induce DHCR24 
expression. This hypothesis was studied by treating the SH-SY5Y-APP751 cells with LXR 
agonists, paxilline and T0901317, and retinoic X receptor (RXR) agonist 9-cis-retinoic acid (9-
cis-RA). No difference in the DHCR24 expression was detected between the agonist- and 
vehicle-treated cells. Expression of two known LXR/RXR target genes, ABCA1 (ATP-binding 
cassette, subfamily A, member 1) and SREBF1 (sterol regulatory element binding 
transcription factor 1) was assessed to validate successful agonist treatment, and indeed 
ABCA1 expression was significantly increased after treatment with paxilline or 9-cis-RA, 
whereas SREBF1 expression was induced with paxilline or T0901317 treatment. Together, 
these findings suggest that DHCR24 expression is not controlled by LXR/RXR system in the 
SH-SY5Y-APP751 cells, and thus LXR/RXR agonist cannot be used to induce DHCR24 
expression in these cells. 
Next, the effects of DHCR24 overexpression upon ER stress and apoptosis induced with 
tunicamycin (TM) or staurosporine (STS), respectively, was studied in the SH-SY5Y-APP751 
cells. Cells were transiently transfected with human DHCR24-containing plasmid to induce 
DHCR24 overexpression, or with a control plasmid. CHOP (C/EBP homologous protein) or 
activated caspase-3 levels were not affected by DHCR24 overexpression in the TM or STS 
treated cells, respectively. Furthermore, DHCR24 overexpression had no effect on cell 
viability under ER stress, apoptotic or normal conditions, suggesting that DHCR24 
overexpression did not protect the cells against these stress conditions. However, DHCR24 
levels were significantly reduced in the STS-treated cells when comparing to vehicle- or TM-
treated cells, probably due to caspase-mediated cleavage as has been reported previously 
(Greeve et al. 2000).    
5.2.3 DHCR24 overexpression increases neuronal viability upon neuroinflammation in 
mouse primary neuron and BV2 microglia cocultures (III) 
Mouse primary cortical neuron and BV2 microglia coculture was utilized to study the effects 
of DHCR24 overexpression in neuroinflammation induced by lipopolysaccharide (LPS) and 
interferon γ (IFN-γ) treatment. To establish the applicability of the selected model, neuronal 
viability and the production of the proinflammatory cytokine tumor necrosis factor α (TNFα) 
and NO was assessed in the cultures without DHCR24 overexpression. The neuronal viability 
was reduced by approximately 40% after LPS and INF-γ treatment, whilst the production of 
TNFα and NO was significantly increased. Furthermore, pre-treatment with anti-
inflammatory cytokine interleukin 10 (IL-10) or inhibitor of iNOS significantly reduced the 
levels of TNF-α by 60% and NO by 90%, respectively. Furthermore, the reduction in NO was 
accompanied with a restoration of the neuronal viability to the levels observed in the vehicle-
treated cultures. TNF-α reduction, however, did not affect the neuronal viability. 
Lentivirus-mediated gene transfer was used to induce human DHCR24 overexpression in 
the mouse primary cortical neurons prior to the addition of the BV2 microglial cells to the 
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culture. Consequently, approximately, a 3-fold increase in the DHCR24 protein levels was 
observed as compared to cocultures with control lentivirus-transduced neurons. 
Interestingly, neuronal viability was significantly increased in the DHCR24-overexpressing 
as compared to control neurons in the LPS- and IFN-γ-treated cocultures. To reveal the 
mechanism behind the increased viability of DHCR24-overexpressing neurons in the 
cocultures, the levels of NO, TNF-α and activated caspase-3 were measured. However, 
DHCR24 overexpression did not have an effect on the TNF-α or NO production, neither on 
the levels of activated caspase-3, suggesting that the protective mechanism of DHCR24 is not 
linked to alleviation of the inflammation response, iNOS activity nor apoptosis. Next, the 
activation of survival signaling pathways was assessed by determining the levels and 
phosphorylation status of Akt and ERK1/2. The total Akt levels were significantly decreased 
and the phosphorylation of Akt was significantly increased upon LPS and INF-γ treatment. 
ERK2 phosphorylation significantly decreased upon LPS and INF-γ treatment.   However, no 
significant differences related to DHCR24-overexpression were detected. Lastly, the effects 
of DHCR24-overexpression on APP processing were assessed. The ratio between mature and 
immature APP was increased in the control-transduced cocultures after induction of 
neuroinflammation as compared to vehicle-treated cocultures. The same effect was not 
observed in the DHCR24-transduced cocultures, indicating that DHCR24 overexpression 
might mitigate the neuroinflammation-induced change in APP maturation. BACE1 levels in 
the cell lysates or Aβ40 levels in the conditioned media were not affected by DHCR24 
overexpression. However, as most of the BACE1 expression in these cocultures results from 
the neurons, BACE1 levels were normalized to neuronal viability and a non-significant 
reduction in BACE1 levels was observed in the DHCR24-overexpressing cultures. Together 
these findings suggest that the neuroprotective mechanism of DHCR24 in the LPS- and IFN-
γ-treated cocultures coincides with reduced maturation of APP695. 
  
43 
 
 
6 Discussion 
6.1 GWAS-IDENTIFIED RISK LOCI CONTRIBUTE TO AD PATHOGENESIS 
During the recent years, large-scale GWA studies have been used to identify new genetic risk 
factors for AD. Currently, over 20 loci have been identified with genome-wide significant 
association with AD. Recently, a meta-analysis by Lambert et al. introduced 11 new loci 
associated with AD (Lambert et al. 2013b). Despite the detected association with AD risk, the 
functional mechanisms and effects on AD pathology of the genes found at these loci remain 
largely unknown, especially for the most recently identified genes. For this reason, the 
association of SNPs within HLA-DRB5, PTK2B, SORL1, SLC24A4, DSG2, INPP5D, MEF2C, 
NME8, CELF1, FERMT2, CASS4 and EPHA1 loci with AD risk and AD-related CSF 
biomarkers was studied in a Finnish case-control cohort.  APOE, which is established as the 
strongest genetic risk factor for AD was included for comparative purposes. Many of the 
single locus associations with AD risk or CSF biomarkers detected in study I did not survive 
correction for multiple testing and are thus only nominally significant. Factors that might 
contribute to the lack of truly significant associations in this study are small sample size, low 
frequency of alternative alleles in some of the studied loci (SORL1 rs1121843, DSG2 
rs8093731, and CASS4 rs7274581) and subtle effects mediated by individual loci. 
Acknowledging that the trends reported here might represent false positive results, these 
findings and their possible implications to AD pathogenesis are discussed below. 
GWAS identified SNPs were first assessed for association with AD risk in the clinical 
cohort, and a trend towards a protective effect was detected for the minor alleles of  SNPs 
rs10498633 and rs11771145, within the SLC24A4 and EPHA1 loci, respectively, similar to 
earlier report (Lambert et al. 2013b). For the other SNPs we did not detect any associations 
with AD risk, which might be due to the relatively small size of our sample set.  
Associations of the GWAS identified susceptibility loci with AD-related CSF biomarkers 
can give insights into their mode of action. Thus, the SNPs were next analyzed for association 
with AD-related CSF biomarkers Aβ42, t-tau and p-tau in a subset of AD-patients of the 
clinical cohort. This kind of assessment has been previously reported only for two of the 
genes selected for this study, APOE and SORL1. As expected based on previous findings 
(Galasko et al. 1998), a significant association was detected between APOE and decreased 
CSF Aβ42 and increased t-tau, respectively. Despite the fact that SORL1 has a role in APP 
processing and thus Aβ production, its relationship with CSF Aβ levels remains controversial 
(Alexopoulos et al. 2011, Kolsch et al. 2008). Although no connection between the SORL1 
rs1121843 and CSF Aβ42 levels was detected in this study, it is possible that this result is 
affected by the low minor allele frequency for this locus among the AD patients in the cohort. 
A trend toward increased CSF Aβ42 levels, indicative of decreased Aβ accumulation in the 
brain, was detected among the minor allele carriers of rs10498633 and rs11771145 within the 
SLC24A4 and EPHA1 loci, respectively. Interestingly, these two SNPs were significantly 
associated with reduced AD risk in the recent meta-analysis (Lambert et al. 2013b) and 
showed a trend toward decreased AD risk in the current study, giving further validation for 
their protective role in AD. Furthermore, variation in EPHA1 locus has previously been 
linked with diminished probability of Aβ-positive findings in the brain of cognitively normal 
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elderly (Hughes et al. 2014). Conversely, no association of the SLC24A4 rs10498633 with Aβ 
has been reported earlier. 
A trend toward association was observed between the minor allele of rs17125944 SNP 
within the FERMT2 locus and decreased levels of both CSF t-tau and p-tau, implying less 
severe neurodegeneration in these individuals. This is an unexpected finding, since the minor 
allele carriers at this locus had significantly increased risk of AD in the published meta-
analysis (Lambert et al. 2013b). The association of FERMT2 with tau, however, is supported 
by a recent finding indicating that the homolog of FERMT2 modulates tau-associated 
pathology in Drosophila melanogaster (Shulman et al. 2014a). Collectively these findings 
suggest that FERMT2 contributes to AD pathology via tau-mediated effects, but further 
studies are required to elucidate the impact of the rs17125944 variant on AD risk and 
pathology. The CELF1 homolog of D. melanogaster was also recently identified as a modulator 
of tau pathology (Shulman et al. 2014a), but no association between the rs10838725 SNP 
within CELF1 locus and t-tau or p-tau levels in the CSF of AD patients was detected in this 
study. However, CELF protein family members are regulators of alternative splicing, and 
other members of the family have been associated with altered splicing of tau in another 
tauopathic disease, DM1 (Leroy et al. 2006, Dhaenens et al. 2011). Therefore, it is possible that 
CELF1 exerts its effect on tau pathology through affecting differential expression of tau 
isoforms rather than by altering tau levels as such.  
Another method to elucidate the possible functions of the susceptibility loci is to assess 
the expression and splicing of the genes within or near the loci. Thus, the expression of APOE, 
BIN1, CLU, ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, CD2AP, FRMD4A, and TREM2 
was assessed in post mortem temporal cortex tissue samples of 60 individuals with varying 
degree of AD-related neurofibrillary pathology. eQTL analysis was carried out to reveal the 
potential effect of the GWAS identified SNP on the gene expression level in the locus. 
Furthermore, the expression levels of the genes in GWAS-identified loci as well as genes 
related to the pathological pathways in AD, namely MAPT, APP, PSEN1, PSEN2, and BACE1, 
were analyzed according to the degree of AD-related neurofibrillary pathology by dividing 
the individuals in three groups according to Braak staging: Braak 0-II, Braak III-IV, and Braak 
V-VI. In addition, the expression levels and SNP genotypes of the GWAS-identified loci were 
studied for associations with biochemical measurements from the temporal cortex tissue 
samples (soluble Aβ42 levels as well the α-, β- and γ-secretase enzymatic activities) and CSF 
Aβ42, t-tau and p-tau levels in a subset of individuals.  No expressional changes were 
detected in the genes related to AD pathological pathways. On the contrary, some genes in 
the GWAS-associated loci showed differing expression levels, as discussed below. Due to the 
expressional changes in the GWAS-identified loci, an in vitro model utilizing PCA and short 
interfering RNA- (siRNA)-mediated silencing was used to reveal whether the altered 
expression might affect the central pathways in AD pathogenesis, Aβ production and tau 
phosphorylation. 
 The rs744373 SNP genotype was found to nominally affect BIN1 expression in the eQTL 
analysis. Although this association was not significant after the correction for multiple 
testing, it is supported by a previous finding showing that a 3bp insertion allele upstream 
BIN1 and residing in the same haplotype block as the rs744373 SNP is associated with BIN1 
expression in the frontal cortex (Chapuis et al. 2013). Furthermore, a positive correlation 
between BIN1 expression and β-secretase activity was detected in the current study. BIN1 
has a role in clathrin-mediated endocytosis, one of the pathways of BACE1 internalization to 
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endocytic compartments, where it is active. Thus, the correlation between BIN1 expression 
and β-secretase activity might be related to the endocytosis rate of BACE1. Other previously 
reported eQTLs include the GWAS-identified SNPs rs11136000 and rs610932 which 
associated with the expression of CLU and MS4A6A, respectively (Allen et al. 2012). These 
results were not replicated in the current study or in another previously published study 
(Karch et al. 2012), possibly due to smaller sample sizes than in the initial study and thus 
reduced statistical power.  
Alternative splicing events were also assessed in the eQTL analysis of this study. 
Alternative splicing of mRNA allows a number of different transcripts and proteins to be 
produced from a single gene, and it has been established that 92-94% of multiexon genes in 
the human genome undergo alternative splicing (Pan et al. 2008). Alternative splicing is 
largely tissue-specific, and as a complex organ, the human brain harbors more alternative 
splicing events than most of the other tissues (Johnson et al. 2009, Yeo et al. 2004). Previous 
studies have suggested splicing changes associated with the GWAS SNPs in the risk genes 
CLU (Szymanski et al. 2011) and CD33 (Malik et al. 2013, Raj et al. 2014). These findings were 
not replicated in the neuropathological cohort of the current study, nor were any other 
splicing changes detected. Again this apparent negative result might be related to the 
relatively small sample size used. 
MS4A6A expression was found to be increased in the temporal cortex according to 
increasing level of AD-related neurofibrillary pathology. MS4A6A is a member of MS4A gene 
cluster containing several genes of close homology. Although the function of MS4A6A is not 
known, other members of the family have been implicated in immune functions and calcium 
homeostasis (Ishibashi et al. 2001). Increased MS4A6A expression in the neuropathological 
cohort is in line with previous reports showing a relationship between increased MS4A6A 
expression and more extensive tau- and Aβ-related neuropathology  (Karch et al. 2012), as 
well as higher levels of MS4A6A in the plasma of AD patients as compared to control 
individuals or subjects with MCI (Proitsi et al. 2014). Unfortunately the MS4A6A expression 
in the HEK293T cells was too low to be detected reliably and thus the functional screening of 
MS4A6A in the PCA reporter system could not be performed. Thus, this study does not 
provide insights for the potential involvement of MS4A6A in Aβ or tau pathways. 
Expression of the FRMD4A gene was significantly downregulated in the temporal cortex 
in relation to increasing level of AD-related neurofibrillary pathology, and functional 
screening in HEK293T cells revealed that FRMD4A downregulation might lead to increased 
Aβ production and alterations in tau phosphorylation. In endothelial cells, FRMD4A is 
involved in the activation of ARF6, which regulates non-clathrin mediated endocytosis and 
actin cytoskeleton and has been suggested to be involved with BACE1 internalization 
(Ikenouchi et al. 2010, Sannerud et al. 2011). Thus, FRMD4A downregulation in the brain 
might have an effect on BACE1 localization in the neurons, which in turn can directly affect 
APP processing and Aβ generation as was observed in HEK293T cells after silencing of 
FRMD4A. Connection to Aβ production is supported by the finding that several FRMD4A 
polymorphisms correlate with plasma levels of Aβ40 and Aβ42 (Lambert et al. 2013a). The 
recent finding of FRMD4A mutations as a cause of recessively inherited severe intellectual 
disability with brain malformations emphasizes the importance of FRMD4A for the normal 
function of the CNS (Fine et al. 2014). 
Two exons of the CLU gene showed a significantly increased expression in relation to 
increasing levels of AD-related neurofibrillary pathology, accompanied with a non-
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significant trend in three other exons, suggesting that the expression of the whole gene is 
increased instead of a change in splicing. This is in line with previous reports of increased 
CLU expression in AD (Allen et al. 2012, Karch et al. 2012). Furthermore, increased levels of 
clusterin protein have been detected in the brain, plasma and CSF of AD patients (Lidstrom 
et al. 1998, Nilselid et al. 2006, Thambisetty et al. 2010, Thambisetty et al. 2012). 
Similar to CLU, the expression of two exons of TREM2 significantly increased according 
to increasing AD-related neurofibrillary pathology with a non-significant increase in the 
3’UTR region suggesting a global increase in the expression. These findings tend to agree 
with a previous finding showing increased Trem2 expression positively correlating to 
increased Aβ levels in the cortex of AD model mice (Guerreiro et al. 2013a, Neumann et al. 
2007). In addition, increased expression of TREM2 in microglia is known to associate with 
enhanced phagocytosis, promotion of the alternative activation state, as well as the 
suppression of cytokine production and secretion (Frank et al. 2008, Piccio et al. 2007, 
Takahashi et al. 2007).  
Increased interaction between APP and BACE1 was detected after silencing of ABCA7, 
leading to increased levels of Aβ in vitro. Recently, six rare loss-of-function mutations in 
ABCA7 were identified in AD patients (Steinberg et al. 2015). These mutations likely lead to 
nonsense-mediated decay of mRNA due to inclusion of a premature stop codon (Steinberg 
et al. 2015). As no protein is produced from the mutation-bearing transcript, this leads to a 
reduction in ABCA7 protein levels. The loss-of-function-induced reduction of ABCA7 is 
effectively modelled by the in vitro silencing approach used in this thesis. Interestingly, the 
silencing of ABCA7 led to increased APP-BACE1-interaction and increased Aβ levels. 
Together these results suggest that reduced levels of ABCA7 protein might contribute to 
increased Aβ production. This is supported by previous findings showing that ABCA7 
overexpression associates with decreased Aβ levels in vitro (Chan et al. 2008) and Abca7-
knock-out mice have increased insoluble Aβ levels (Kim et al. 2013). Increased Aβ production 
might be the result of reduced ABCA7 levels in the neurons, however, in addition to neurons, 
ABCA7 is also expressed at high levels in microglia (Kim et al. 2006). Given that phagocytosis 
is suggested as the main function of ABCA7 in macrophage cells (Jehle et al. 2006, Vasquez 
et al. 2013), it is possible that decreased ABCA7 levels in the microglia lead to impaired 
phagocytosis of cell debris, which in addition to increased Aβ would further facilitate the 
pathogenesis of AD. 
As the effect of individual risk variants is often very small, a polygenic risk score approach 
has been developed to enable collective analysis of several risk variants. This method has 
been successfully used in other diseases with complex genetics, such as schizophrenia 
(International Schizophrenia Consortium et al. 2009). In this study, a polygenic risk score 
combining 22 AD-associated SNPs (Table 4) was calculated for each individual in the clinical 
and neuropathological cohorts, utilizing the ORs reported in the previously published meta-
analyses (Lambert et al. 2013b, http://www.alzgene.org/, Table 1). As the OR of APOE is 
considerably higher than that of the other variants, the APOE genotype is bound to have a 
large impact on the risk score value of each individual. Thus, a non-APOE polygenic risk 
score was also calculated. The polygenic AD risk score was found to correlate positively with 
soluble Aβ42 levels in the temporal cortex of the neuropathological cohort, suggesting that 
the risk variants might affect the Aβ levels. This association remained significant when APOE 
was removed from the risk score, suggesting that the other risk variants also significantly 
affect Aβ levels. Similarly, the polygenic risk scores both with and without APOE 
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significantly associated with CSF Aβ42 levels in the clinical cohort. Only APOE risk score was 
found to associate with CSF t-tau or p-tau levels, indicating that the other risk variants do 
not strongly affect the tau pathway in AD. Of particular interest was the finding that the non-
APOE risk score significantly, positively, correlated with γ-secretase activity in the temporal 
cortex, whereas this association vanished when APOE was included in the risk score, 
suggesting an APOE-independent effect on γ-secretase activity, which might partially explain 
the association with Aβ levels. Together these findings suggest that AD-associated risk 
variants affect the Aβ pathway, potentially via modulation of the γ-secretase activity. 
In the clinical setting, it would be extremely important to be able to identify early enough 
the individuals with an increased risk to develop AD. Recently, a polygenic risk score based 
on 11 AD risk genes was used to predict conversion to AD in a population-based cohort, and 
it was found that the polygenic score only marginally improved the prediction of AD as 
compared to the determination of the individuals’ APOE status only (Verhaaren et al. 2013). 
Together with the results of the current study, this suggests that genetic profiling based on 
the currently known significant risk SNPs might not provide enough discriminative accuracy 
to be feasible for diagnostic use at the moment. However, a similar follow-up study in a 
population based cohort or within a selected cohort of individuals with MCI might be used 
to evaluate whether the polygenic risk score based on 22 loci used in the current study would 
provide better accuracy in predicting conversion to AD. It has been argued that the predictive 
accuracy of the polygenic models could be improved by including nominally significant 
GWAS loci; however this might be limited to the cases when only a few significant GWAS 
risk variants are available (Evans et al. 2009). In contrast, when more risk variants have been 
identified, the addition of a number of potentially false positive loci might dilute the results 
obtained with only the significant loci (Evans et al. 2009). Furthermore, it has been shown 
that considering all common SNPs together, regardless of their significance, can explain a 
large proportion of the heritability which remains undetected when considering only the 
significant GWAS SNPs (Lee et al. 2012, Yang et al. 2010). Although the latter approach might 
greatly improve the accuracy of risk prediction, such genome-wide genotyping efforts are 
not likely to be adopted in clinical use in the near future. 
6.2 FUNCTIONAL STUDIES REVEAL POTENTIAL THERAPEUTIC TARGETS 
IN AD 
Accumulating data suggest that DHCR24 can protect neuronal cells during different AD-
related stress conditions (Cecchi et al. 2008, Crameri et al. 2006, Greeve et al. 2000, Kuehnle 
et al. 2008, Lu et al. 2014, Wu et al. 2004). Thus increasing DHCR24 expression has been 
suggested as a potential therapeutic strategy in AD. In this study, the role of DHCR24 
overexpression during ER stress, apoptosis and neuroinflammation was assessed using in 
vitro models. Furthermore, pharmacological induction of LXR/RXR system was tested as a 
mean to augment DHCR24 expression. 
Apoptosis and ER stress were studied using transient transfection of human DHCR24 in 
human neuroblastoma SH-SY5Y-APP751 secondary cell line. Prior to the stress treatments, 
basic characterization of the model in basal conditions was carried out by assessing APP 
processing and total cholesterol levels. APP levels significantly increased in DHCR24-
overexpressing SH-SY5Y-APP751 cells. APP cleavage products, C83, C99, sAPPα, Aβ40, and 
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Aβ42 were next analyzed and slight reductions in their levels were detected when 
normalized to total APP. Cycloheximide time course analysis showed that DHCR24-
overexpression had no effect on APP half-life, thus APP degradation is not likely to be 
affected by DHCR24. Together these findings suggest an overall reduction of APP processing 
in DHCR24-overexpressing cells, resulting in the accumulation of total APP. This finding is 
in line with a previous report suggesting that DHCR24 downregulation in SH-SY5Y-APP751 
increased APP processing (Sarajarvi et al. 2009). These results could not be replicated in the 
mouse primary neuron and BV2 microglia coculture used in the current study, suggesting 
that the effect of DHCR24 on APP might be cell line or species-specific. No differences in the 
total cellular cholesterol levels were detected between DHCR24-overexpressing and control-
transfected SH-SY5Y-APP751 cells during normal growth conditions. This was an 
unexpected finding, as previous reports using the same SH-SY5Y cell line have shown 
increased membrane and total cholesterol levels upon overexpression of DHCR24 (Cecchi et 
al. 2008, Crameri et al. 2006, Kuehnle et al. 2008). The underlying mechanisms for these 
conflicting results remain unclear and warrant further investigation, such as determination 
of the membrane cholesterol levels, as the previous studies have shown greater difference in 
the membrane cholesterol levels between DHCR24-overexpressing and control cells as 
compared to the total cholesterol. 
No alleviation of ER stress, as indicated by CHOP protein levels, was detected in SH-SY5Y-
APP751 cells in this study, in contrast to a recent report showing that DHCR24 
overexpression protected cells from ER stress-induced apoptosis (Lu et al. 2014). This 
discrepancy is likely caused by differences in the experimental conditions, as the previous 
studies have used longer, 12–48h, treatment times with TM instead of 6h used in this study 
(Lu et al. 2008, Lu et al. 2014). Previously, neuroprotective effects of DHCR24 have also been 
linked to reduced activation of caspase-3 (Greeve et al. 2000, Lu et al. 2014), and increased 
caspase-3 activation has been detected when DHCR24 was down-regulated in apoptotic 
conditions (Sarajarvi et al. 2009). Contrary to these reports, no difference in caspase-3 
activation was detected between DHCR24-overexpressing and control cells during STS-
induced apoptosis in the SH-SY5Y-APP751 cells used in this study. Cell viability was not 
affected by DHCR24 overexpression in this model, which is in line with the caspase-3 finding. 
Together these findings suggest that decreased levels of DHCR24 might aggravate the 
caspase-3 activation upon apoptotic conditions, but overexpression of DHCR24 does not 
have additional protective effect when compared to the endogenously expressed DHCR24. 
Furthermore, cholesterol activity has been shown previously to be directly involved in the 
protective effect of DHCR24 (Cecchi et al. 2008, Crameri et al. 2006, Kuehnle et al. 2008), but 
DHCR24 overexpression had no effect on the cholesterol levels of SH-SY5Y-APP751 cells in 
the basal conditions in the current study. It is therefore possible that the neuroprotective 
effects of DHCR24 upon ER stress and apoptosis are related to the cholesterol activity. 
However, as the cholesterol levels were not determined after induction of ER stress and 
apoptosis in this study, no definitive conclusions can be drawn. 
LXRs (LXRα and LXRβ encoded by NR1H3 and NR1H2 genes, respectively) and RXRs are 
ligand-activated nuclear receptors, which as heterodimers regulate the expression of their 
target genes. The LXR/RXR system gained considerable interest in the AD field when the 
RXR agonist bexarotene was reported to improve cognition, reverse neurodegeneration and 
clear Aβ in a transgenic AD mouse model (Cramer et al. 2012). The DHCR24 promoter area 
was identified to harbor an LXRα response element, and thus it was hypothesized, that 
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activation of the LXR/RXR system could be used to induce DHCR24 expression (Wang et al. 
2008). Inconclusive support for this hypothesis was gained from LXRβ-null mice, as DHCR24 
levels in the skin cells of these mice were significantly reduced as compared to wild type 
litter mates, but no difference was detected in the brain (Wang et al. 2008). The results of the 
current study suggest that DHCR24 expression is not controlled by LXR/RXR system in the 
SH-SY5Y-APP751 human neuroblastoma cell line, as no difference in DHCR24 mRNA levels 
were detected between agonist-treated and untreated cells. The expression of known 
LXR/RXR target genes ABCA1 and SREBF1 was increased after the agonist treatments, which 
confirms that the treatment was successful. Contrasting results have been obtained in a 
human medulloblastoma cell line, where transcriptional activation of DHCR24 promoter was 
detected in response to treatment with LXR agonist T0901317 (Ishida et al. 2013b). This report 
also indicated competitive binding of LXR and thyroid hormone receptor to the same 
response element on DHCR24 promoter. Furthermore, in mice LXR agonist T0901317 
induced DHCR24 expression only in hypothyroid state or in animals with mutated thyroid 
hormone receptor (Ishida et al. 2013a). Together these results suggest condition-dependent 
regulation of DHCR24 by the LXR/RXR system, thus pharmacological induction of LXR/RXR 
might not be a feasible strategy in elevating DHCR24 levels. 
Neuroinflammation due to activation of glial cells is a central feature in AD and other 
neurodegenerative diseases, but surprisingly DHCR24 has not been studied in the context of 
neuroinflammation before. In this study, a coculture of mouse primary cortical neurons and 
BV2 microglia was used to study neuroinflammation induced by LPS and IFN-γ treatment. 
Characterization of the neuroinflammation model revealed increased levels of pro-
inflammatory cytokine TNFα and NO, and increased activation of caspase-3 in the LPS and 
IFN-γ treated cultures. Neuronal viability was reduced by approximately 40% after treatment 
with LPS and IFN-γ as compared to vehicle-treated samples. Pretreatment with selective 
iNOS inhibitor 1400W significantly decreased NO levels and increased neuronal viability, 
whereas pretreatment with the anti-inflammatory cytokine IL-10 decreased the levels of 
TNFα but had no effect on neuronal viability. Together these results suggest that 
neuroinflammation was successfully induced in the model, and that the neuronal viability 
negatively correlated with NO production.  
Next, lentivirus-mediated gene transfer was used to induce human DHCR24 
overexpression in the primary neurons before BV2 microglia were added to the culture, thus 
resulting in neuron-specific DHCR24 overexpression. Intriguingly, viability of the DHCR24-
overexpressing neurons in the cocultures was significantly increased as compared to control-
transduced neurons upon LPS and IFN-γ treatment. No effect on viability was seen in the 
vehicle-treated cocultures, thus suggesting that DHCR24 is protective upon 
neuroinflammatory stress condition. Different pathways were studied in attempt to reveal 
the specific mechanism behind DHCR24-mediated neuroprotection. DHCR24 
overexpression was not found to affect activation of caspase-3, nor the levels of NO and TNFα 
in the conditioned media. Activation of cell survival signaling pathways were studied by 
assessing the levels of total and phosphorylated Akt as well as ERK1 and ERK2, but no 
differences were detected related to DHCR24 overexpression, suggesting that DHCR24 does 
not affect these signaling pathways. Furthermore, APP, Aβ40, and BACE1 levels were 
assessed to see whether the amyloidogenic pathway is affected by DHCR24 overexpression. 
An increased ratio of mature to immature APP was detected in the control-transduced 
cultures upon neuroinflammation, whereas the ratio in DHCR24-transduced cultures 
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remained similar to the vehicle-treated cultures. However, it remains unclear whether this 
APP maturation effect is causally linked to the increased neuronal viability in the DHCR24-
overexpressing neurons upon neuroinflammation. BACE1 levels in the cell lysates or Aβ40 
levels in the conditioned media were not affected by DHCR24 overexpression. However, as 
most of the BACE1 expression in these cocultures results from the neurons, BACE1 levels 
were normalized to neuronal viability and a non-significant reduction in BACE1 levels was 
observed in the DHCR24-overexpressing cultures. Previously, downregulation of DHCR24 
in apoptotic conditions has been shown to result in stabilization of BACE1 due to enhanced 
depletion of GGA3 which is responsible for lysosomal targeting of BACE1 (Sarajarvi et al. 
2009). It is thus possible, that DHCR24 overexpression might mitigate the 
neuroinflammation-induced increase in BACE1 levels.   
In conclusion, DHCR24 was shown to protect neuronal cells from neuroinflammation 
induced by microglial activation. Multiple pathways potentially leading to neuroprotection 
were studied, but the specific mechanism mediating the neuroprotective effects of DHCR24 
was not identified in this study. However, the neurotoxic effects of reactive microglia might 
be mediated by ROS (Heneka et al. 2015), and DHCR24 has been shown to scavenge H2O2 
and protect cells from oxidative stress (Greeve et al. 2000, Kuehnle et al. 2008, Lu et al. 2008). 
Decreased ROS levels were also recently reported in DHCR24-overexpressing cells 
undergoing ER-stress (Lu et al. 2014). Thus, ROS scavenging is a possible candidate as a 
mediator of the protective effects of DHCR24 upon neuroinflammation.  
LRP1 mediates transcytosis of Aβ across the BBB, regulates Aβ uptake and degradation in 
several cell types in the brain, and maintains a peripheral Aβ sink by uptake for degradation 
in the liver and retaining sLRP1-bound Aβ in the plasma. This major involvement in 
regulating the Aβ homeostasis in the CNS makes LRP1 an attractive therapeutic target in AD. 
Reports of decreased LRP1 levels due to aging and in AD support the hypothesis, that 
therapies aimed at restoring or increasing the LRP1 levels might be beneficial in treating AD 
patients. However, LRP1 is a receptor for multiple ligands and adverse side-effects are 
possible when LRP1 is targeted. Furthermore, LRP1 has been shown to have a role in APP 
endocytosis and Aβ production, and thus promoting LRP1 levels might also lead to increased 
amyloidogenic processing of APP and accumulation of Aβ. 
Some potential methods to increase LRP1 expression have been reported in the literature. 
Cholesterol-lowering statin (hydroxymethylglutaryl-CoA reductase inhibitor) fluvastatin 
has been shown to increase the levels of LRP1 in mouse cerebral vessels, leading to reduced 
brain Aβ levels (Shinohara et al. 2010). Furthermore, another drug of the statin group, 
atorvastatin, increased LRP1 levels in the rat liver (Moon et al. 2011), which might enhance 
the peripheral clearance of Aβ. Widely used antibiotic rifampicin was reported to increase 
LRP1 expression in the brain endothelial cells and brain microvessels of wild-type mice and 
led to increased Aβ efflux (Qosa et al. 2012). In addition, the root extract of an auyrverdic 
herb, Withania somnifera, has been reported to significantly increase the levels of hepatic LRP1 
and sLRP1, leading to a decreased Aβ burden and reversal of behavioral deficits in two 
strains of AD model mice (Sehgal et al. 2012).  
A more selective increase in LRP1 levels could be achieved by gene therapy, where it 
would be possible to direct the effect on a distinct cell type or tissue of choice (Sagare et al. 
2012). The possibility to systemically administer LRP1-based gene therapy targeted to the 
BBB endothelial cells or liver makes them more feasible targets than gene therapy targeted 
to the brain, which would require transfer across the BBB. Among the more specific LRP1-
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based therapeutic options is also targeting sLRP1 in the plasma. Reduced total levels of 
sLRP1 and increased oxidation leading to lower affinity for Aβ have been reported in the 
plasma of AD patients (Sagare et al. 2007). Levels of oxidized sLRP1 have been suggested as 
an antecedent biomarker for AD, although the studied cohort was relatively small and thus 
further studies in a larger cohort would be needed to evaluate the biomarker potential 
(Sagare et al. 2011). Interestingly, intravenous administration of recombinant Aβ-binding 
domain of LRP1 known as cluster IV (LRP-IV) effectively cleared Aβ from the brain of AD 
mouse model, and led to improvements in behavioral dysfunctions (Sagare et al. 2007). 
Furthermore, LRP-IV was shown to have higher affinity for Aβ than the endogenous sLRP1, 
and incubation of LRP-IV with plasma samples of AD patients led to an effective clearance 
of free Aβ40 and Aβ42. These findings suggest that enhancing the peripheral sink for Aβ by 
administration of LRP-IV or similar recombinant receptors might be a feasible option in the 
treatment or prevention of AD. 
In conclusion, different LRP1-based therapies have been studied in AD models both in 
vitro and in vivo and promising results related to lowered Aβ levels and restoration of 
cognitive dysfunctions have been reported. The possibility to target LRP1 in liver, plasma or 
BBB would make it a feasible option compared to therapeutics that need to be delivered to 
the brain, directly or across the BBB. However, further characterization in different AD 
models is required to evaluate the suitability of these therapies for clinical trials with AD 
patients. As the APOE genotype has been shown to affect LRP1-mediated Aβ-clearance, it is 
possible that any given type of LRP1-based therapy might not be suitable for all individuals 
and different approaches might need to be used based on the APOE genotype and other 
factors. It also remains to be determined whether the augmentation of LRP1 levels or function 
in humans could be achieved with pharmacological or some other strategies, such as gene 
therapy or recombinant protein delivery systems. In addition, special emphasis should be 
laid on developing treatment options avoiding possible adverse side effects due to alterations 
in the metabolism of other LRP1 ligands or amyloidogenic processing of APP. However, 
great potential for targeting AD pathogenesis lies within LRP1, as it provides multiple sites 
for treatment including the CNS, BBB, and periphery.  
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7 Summary and Conclusions 
I AD risk SNPs at the SLC24A4, EPHA1 and FERMT2 loci nominally associate with 
AD-related CSF biomarkers. GWAS-identified AD risk loci combined to a 
polygenic risk score contribute to the AD-related changes in Aβ42 levels in the CSF 
and the brain independently of the strongest genetic risk factor, APOE. This effect 
might be at least partially mediated by increased γ-secretase activity.  
II AD risk genes MS4A6A, FRMD4A, CLU and TREM2 are differentially expressed 
during progression of AD-related neurofibrillary pathology. BIN1 expression is 
nominally associated with a GWAS-identified risk SNP. FRMD4A and ABCA7 
functionally associate with Aβ production pathway, and FRMD4A and CD2AP 
functionally associate with regulation of tau phosphorylation in vitro. 
III Augmentation of DHCR24 levels increases neuronal viability by protecting the 
neurons against the harmful effects mediated by activated microglia during 
neuroinflammation in vitro. Together with previous reports, these findings suggest 
that DHCR24 has neuroprotective effects in many different stress conditions linked 
to AD and other neurodegenerative diseases, and thus might prove useful when 
considering new therapeutic strategies for AD.  
IV LRP1 has a central role as a receptor mediating the clearance of Aβ in the brain, 
across the BBB to periphery and within the periphery. Different pharmacological or 
gene therapy-based methods increasing LRP1 or sLRP1 levels might be a feasible 
alternative for currently considered passive immunization or secretase inhibitor- or 
modulator-based methods when considering Aβ lowering therapies in AD. 
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